<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GARDASIL - human papillomavirus type 11 l1 capsid protein antigen, human papillomavirus type 18 l1 capsid protein antigen, human papillomavirus type 16 l1 capsid protein antigen and human papillomavirus type 6 l1 capsid protein antigen injection, suspension </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use GARDASIL safely and effectively. See full prescribing information for GARDASIL.GARDASIL®[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]Suspension for intramuscular injectionInitial U.S. Approval: 2006</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:</p>
<ul>
<li>Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span> (condyloma acuminata) caused by HPV types 6 and 11 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
</ul>
<p>And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</span> (CIN) grade 2/3 and Cervical adenocarcinoma <span class="Italics">in situ</span> (AIS) (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</span> (CIN) grade 1 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
<li>Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
<li>Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
<li>Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (<a href="#i4i_section_id_9a7106d8-86fc-45f4-8e23-ddd7fb0697a4">1.1</a>)</li>
</ul>
<p>GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases caused by HPV types included in the vaccine:</p>
<ul>
<li>Anal cancer caused by HPV types 16 and 18 (<a href="#i4i_section_id_4f575031-a5d8-48c5-bfb6-537ded65289b">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span> (condyloma acuminata) caused by HPV types 6 and 11 (<a href="#i4i_section_id_4f575031-a5d8-48c5-bfb6-537ded65289b">1.2</a>)</li>
</ul>
<p>And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:</p>
<ul><li>Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (<a href="#i4i_section_id_4f575031-a5d8-48c5-bfb6-537ded65289b">1.2</a>)</li></ul>
<p>Limitations of GARDASIL Use and Effectiveness:</p>
<ul>
<li>GARDASIL does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>) (<a href="#i4i_info_patients_id_9f9f63ed-ff75-4af6-841b-75c93c925255">17</a>)</li>
<li>Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>) (<a href="#i4i_info_patients_id_9f9f63ed-ff75-4af6-841b-75c93c925255">17</a>)</li>
<li>GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>) (<a href="#i4i_section_id_7a7e4db4-31de-41e7-b152-106084083608">14.4</a>) (<a href="#i4i_section_id_c7f5fcef-f532-49b2-920f-1b64564a90bc">14.5</a>)</li>
<li>GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, vaginal, and anal cancers; CIN; VIN; VaIN, or AIN. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>)</li>
<li>GARDASIL has not been demonstrated to protect against diseases due to HPV types not contained in the vaccine. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>) (<a href="#i4i_section_id_7a7e4db4-31de-41e7-b152-106084083608">14.4</a>) (<a href="#i4i_section_id_85e7fa84-9c11-441a-b13f-d82e06f70bb9">14.5</a>) </li>
<li>Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL protects only against those vulvar, vaginal, and anal cancers caused by HPV 16 and 18. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>)</li>
<li>GARDASIL does not protect against genital diseases not caused by HPV. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>)</li>
<li>Vaccination with GARDASIL may not result in protection in all vaccine recipients. (<a href="#i4i_section_id_422c1b20-2f86-446a-81a0-bc6efbdd5bdf">1.3</a>)</li>
<li>GARDASIL has not been demonstrated to prevent HPV-related CIN 2/3 or worse in women older than 26 years of age. (<a href="#i4i_section_id_13c7021d-314b-4601-acc5-e7b2dbe0b685">14.7</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p> GARDASIL® is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: </p>
<ul>
<li>Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18</li>
<li> <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span> (condyloma acuminata) caused by HPV types 6 and 11 </li>
</ul>
<p> And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: </p>
<ul>
<li> <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</span> (CIN) grade 2/3 and Cervical adenocarcinoma <span class="Italics">in situ</span> (AIS) </li>
<li> <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</span> (CIN) grade 1 </li>
<li> Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 </li>
<li> Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 </li>
<li>Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3</li>
</ul>
<p>
 
</p>
<p></p>
<p>GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases caused by HPV types included in the vaccine:</p>
<ul>
<li>Anal cancer caused by HPV types 16 and 18</li>
<li><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span> (condyloma acuminata) caused by HPV types 6 and 11</li>
</ul>
<p>And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:</p>
<ul><li>Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3</li></ul>
<p>
 
</p>
<p></p>
<p>The health care provider should inform the patient, parent, or guardian that vaccination does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care. <span class="Italics">[See <a href="#i4i_info_patients_id_9f9f63ed-ff75-4af6-841b-75c93c925255">Patient Counseling Information (17)</a>.] </span></p>
<p>Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider. <span class="Italics">[See <a href="#i4i_info_patients_id_9f9f63ed-ff75-4af6-841b-75c93c925255">Patient Counseling Information (17)</a>.]</span></p>
<p>GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity. <span class="Italics">[See Clinical Studies (<a href="#i4i_section_id_7a7e4db4-31de-41e7-b152-106084083608">14.4</a>, <a href="#i4i_section_id_c7f5fcef-f532-49b2-920f-1b64564a90bc">14.5</a>).]</span></p>
<p>GARDASIL is not intended to be used for treatment of active external genital lesions; cervical, vulvar, vaginal, and anal cancers; CIN; VIN; VaIN; or AIN.</p>
<p>GARDASIL has not been demonstrated to protect against diseases due to HPV types not contained in the vaccine. <span class="Italics">[See Clinical Studies (<a href="#i4i_section_id_7a7e4db4-31de-41e7-b152-106084083608">14.4</a>, <a href="#i4i_section_id_c7f5fcef-f532-49b2-920f-1b64564a90bc">14.5</a>).]</span></p>
<p>Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL protects only against those vulvar, vaginal, and anal cancers caused by HPV 16 and 18.</p>
<p>GARDASIL does not protect against genital diseases not caused by HPV.</p>
<p>Vaccination with GARDASIL may not result in protection in all vaccine recipients.</p>
<p>GARDASIL has not been demonstrated to prevent HPV-related CIN 2/3 or worse in women older than 26 years of age. <span class="Italics">[See <a href="#i4i_section_id_13c7021d-314b-4601-acc5-e7b2dbe0b685">Clinical Studies (14.7)</a>.]</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months. (<a href="#i4i_section_id_363afa75-9a54-4e95-a4b3-47836f6df349">2.1</a>)</p>
<p>
 
</p>
<p></p>
<p>GARDASIL should be administered intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months. <span class="Italics">[See <a href="#i4i_section_id_aba183ca-227e-435d-a6ec-59a29880dc44">Clinical Studies (14.8)</a>.]</span></p>
<p>
 
</p>
<p></p>
<p>For intramuscular use only.</p>
<p>Shake well before use. Thorough <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> immediately before administration is necessary to maintain suspension of the vaccine. GARDASIL should not be diluted or mixed with other vaccines. After thorough <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, GARDASIL is a white, cloudy liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the product if particulates are present or if it appears discolored.</p>
<p>GARDASIL should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. </p>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> has been reported following vaccination with GARDASIL and may result in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury; observation for 15 minutes after administration is recommended. <span class="Italics">[See <a href="#i4i_section_id_7cd660cb-66d5-4f11-8b92-381f43c676f1">Warnings and Precautions (5.1)</a>.]</span></p>
<p><span class="Italics">Single-Dose Vial Use</span></p>
<p>Withdraw the 0.5-mL dose of vaccine from the single-dose vial using a sterile needle and syringe and use promptly. </p>
<p><span class="Italics">Prefilled Syringe Use</span></p>
<p>This package does not contain a needle. Shake well before use. Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe. Administer the entire dose as per standard protocol.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>GARDASIL is a suspension for intramuscular administration available in 0.5-mL single dose vials and prefilled syringes. See <span class="Italics"><a href="#i4i_description_id_760ef330-cc9d-4589-8a04-df27390a962b"> Description (11)</a></span> for the complete listing of ingredients.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to yeast (a vaccine component), or after a previous dose of GARDASIL. <span class="Italics">[See <a href="#i4i_description_id_760ef330-cc9d-4589-8a04-df27390a962b">Description (11)</a>.]</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul><li>Because vaccinees may develop <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, sometimes resulting in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury, observation for 15 minutes after administration is recommended. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, sometimes associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> and other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-like activity, has been reported following vaccination with GARDASIL. When <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> is associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span>, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position. (<a href="#i4i_section_id_7cd660cb-66d5-4f11-8b92-381f43c676f1">5.1</a>)</li></ul>
<p>
 
</p>
<p></p>
<p> Because vaccinees may develop <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, sometimes resulting in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury, observation for 15 minutes after administration is recommended. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, sometimes associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> and other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-like activity, has been reported following vaccination with GARDASIL. When <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> is associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span>, the activity is usually transient and typically responds to restoring cerebral perfusion by maintaining a supine or Trendelenburg position. </p>
<p>
 
</p>
<p></p>
<p>Appropriate medical treatment and supervision must be readily available in case of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> following the administration of GARDASIL.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p><span class="Italics">Overall Summary of Adverse Reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; and local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>) occurred after administration with GARDASIL. </p>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, sometimes associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> and other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-like activity, has been reported following vaccination with GARDASIL and may result in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury; observation for 15 minutes after administration is recommended. <span class="Italics">[See <a href="#i4i_section_id_7cd660cb-66d5-4f11-8b92-381f43c676f1">Warnings and Precautions (5.1)</a>.]</span> </p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported following vaccination with GARDASIL. </p>
<p>
 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. </p>
<p><span class="Italics">Studies in Girls and Women (9 Through 45 Years of Age) and Boys and Men (9 Through 26 Years of Age)</span></p>
<p>In 7 clinical trials (5 Amorphous Aluminum Hydroxyphosphate Sulfate [AAHS]-controlled, 1 saline placebo-controlled, and 1 uncontrolled), 18,083 individuals were administered GARDASIL or AAHS control or saline placebo on the day of enrollment, and approximately 2 and 6 months thereafter, and safety was evaluated using vaccination report cards (VRC)-aided surveillance for 14 days after each injection of GARDASIL or AAHS control or saline placebo in these individuals. The individuals who were monitored using VRC-aided surveillance included 10,088 individuals 9 through 45 years of age at enrollment who received GARDASIL and 7,995 individuals who received AAHS control or saline placebo. Few individuals (0.2%) discontinued due to adverse reactions. The race distribution of the 9- through 26-year-old girls and women in the safety population was as follows: 62.3% White; 17.6% Hispanic (Black and White); 6.8% Asian; 6.7% Other; 6.4% Black; and 0.3% American Indian. The race distribution of the 24- through 45-year-old women in the safety population of Study 6 was as follows: 20.6% White; 43.2% Hispanic (Black and White); 0.2% Other; 4.8% Black; 31.2% Asian; and 0.1% American Indian. The race distribution of the 9- through 26-year-old boys and men in the safety population was as follows: 42.0% White; 19.7% Hispanic (Black and White); 11.0% Asian; 11.2% Other; 15.9% Black; and 0.1% American Indian.</p>
<p><span class="Italics">Common Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age</span></p>
<p>The injection site adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients are shown in Table 1.</p>
<a name="id_c3216ca6-4c39-4aff-8adb-21e9a842ebc3"></a><table width="576.000">
<caption><span>Table 1: Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age<a href="#footnote-1">*</a></span></caption>
<col span="1" width="29.5%">
<col span="1" width="22.9%">
<col span="1" width="23.8%">
<col span="1" width="23.8%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">Adverse Reaction</span></p>
<p>(1 to 5 Days Postvaccination)</p>
</td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>
<p>(N = 5088)</p>
<p>%</p>
</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-2">†</a></span></p>
<p>(N = 3470)</p>
<p>%</p>
</td>
<td>
<p class="First"><span class="Bold">Saline</span></p>
<p><span class="Bold">Placebo</span></p>
<p>(N = 320)</p>
<p>%</p>
</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Italics">Injection Site</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span></p>
</td>
<td>
<br><p class="First">83.9</p>
<p>25.4</p>
<p>24.7</p>
<p>3.2</p>
<p>2.8</p>
</td>
<td>
<br><p class="First">75.4</p>
<p>15.8</p>
<p>18.4</p>
<p>2.8</p>
<p>3.2</p>
</td>
<td>
<br><p class="First">48.6</p>
<p>7.3</p>
<p>12.1</p>
<p>0.6</p>
<p>1.6</p>
</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p><span class="Italics">Common Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age</span></p>
<p>The injection site adverse reactions that were observed among recipients of GARDASIL at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients are shown in Table 2.</p>
<a name="id_a4a4ce2b-efa4-4ecc-9195-41d5fbd84b42"></a><table width="577.000">
<caption><span>Table 2: Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age<a href="#footnote-3">*</a></span></caption>
<col span="1" width="28.6%">
<col span="1" width="22.9%">
<col span="1" width="23.7%">
<col span="1" width="24.8%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">Adverse Reaction</span></p>
<p>(1 to 5 Days Postvaccination)</p>
</td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>
<p>(N = 3093)</p>
<p>%</p>
</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-4">†</a></span></p>
<p>(N = 2029)</p>
<p>%</p>
</td>
<td>
<p class="First"><span class="Bold">Saline</span></p>
<p><span class="Bold">Placebo</span></p>
<p>(N = 274)</p>
<p>%</p>
</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Italics">Injection Site </span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></p>
<p>    <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></p>
</td>
<td>
<br><p class="First">61.4</p>
<p>16.7</p>
<p>13.9</p>
<p>1.0</p>
</td>
<td>
<br><p class="First">50.8</p>
<p>14.1</p>
<p>9.6</p>
<p>0.3</p>
</td>
<td>
<br><p class="First">41.6</p>
<p>14.5</p>
<p>8.2</p>
<p>3.3</p>
</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p><span class="Italics">Evaluation of Injection-Site Adverse Reactions by Dose in Girls and Women 9 Through 26 Years of Age</span></p>
<p>An analysis of injection-site adverse reactions in girls and women by dose is shown in Table 3. Of those girls and women who reported an injection-site reaction, 94.3% judged their injection-site adverse reaction to be mild or moderate in intensity.</p>
<a name="id_31fee3d2-c9ce-4246-9a6f-3072d43bc332"></a><table width="762">
<caption><span>Table 3: Postdose Evaluation of Injection-Site Adverse Reactions in Girls and Women 9 Through 26 Years of Age (1 to 5 Days Postvaccination)</span></caption>
<col span="1" width="14.4%">
<col span="1" width="10.1%">
<col span="1" width="9.3%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="9.3%">
<col span="1" width="10.1%">
<col span="1" width="9.3%">
<col span="1" width="8.7%">
<col span="1" width="8.7%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-5">*</a></span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">Saline Placebo</span></p>(% occurrence)</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Adverse</span></p>
<span class="Bold">Reaction</span>
</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N<a href="#footnote-6">†</a> = 5011</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 4924</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 4818</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N = 3410</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 3351</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 3295</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N = 315</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 301</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 300</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">63.4</p>
<p>62.5</p>0.9</td>
<td>
<p class="First">60.7</p>
<p>59.7</p>1.0</td>
<td>
<p class="First">62.7</p>
<p>61.2</p>1.5</td>
<td>
<p class="First">57.0</p>
<p>56.6</p>0.4</td>
<td>
<p class="First">47.8</p>
<p>47.3</p>0.5</td>
<td>
<p class="First">49.6</p>
<p>48.9</p>0.6</td>
<td>
<p class="First">33.7</p>
<p>33.3</p>0.3</td>
<td>
<p class="First">20.3</p>
<p>20.3</p>0.0</td>
<td>
<p class="First">27.3</p>
<p>27.0</p>0.3</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></span><a href="#footnote-7">‡</a></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">10.2</p>
<p>9.6</p>0.6</td>
<td>
<p class="First">12.8</p>
<p>11.9</p>0.8</td>
<td>
<p class="First">15.1</p>
<p>14.2</p>0.9</td>
<td>
<p class="First">8.2</p>
<p>8.1</p>0.2</td>
<td>
<p class="First">7.5</p>
<p>7.2</p>0.2</td>
<td>
<p class="First">7.6</p>
<p>7.3</p>0.2</td>
<td>
<p class="First">4.4</p>
<p>4.4</p>0.0</td>
<td>
<p class="First">3.0</p>
<p>3.0</p>0.0</td>
<td>
<p class="First">3.3</p>
<p>3.3</p>0.0</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></span><a href="#footnote-7" class="Sup">7</a></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">9.2</p>
<p>9.0</p>0.2</td>
<td>
<p class="First">12.1</p>
<p>11.7</p>0.3</td>
<td>
<p class="First">14.7</p>
<p>14.3</p>0.4</td>
<td>
<p class="First">9.8</p>
<p>9.5</p>0.3</td>
<td>
<p class="First">8.4</p>
<p>8.4</p>0.1</td>
<td>
<p class="First">8.9</p>
<p>8.8</p>0.1</td>
<td>
<p class="First">7.3</p>
<p>7.3</p>0.0</td>
<td>
<p class="First">5.3</p>
<p>5.3</p>0.0</td>
<td>
<p class="First">5.7</p>
<p>5.7</p>0.0</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p><a name="footnote-reference-7" href="#footnote-7" class="Sup">7</a></p>
<p><span class="Italics">Evaluation of Injection-Site Adverse Reactions by Dose in Boys and Men 9 Through 26 Years of Age </span></p>
<p>An analysis of injection-site adverse reactions in boys and men by dose is shown in Table 4. Of those boys and men who reported an injection-site reaction, 96.4% judged their injection-site adverse reaction to be mild or moderate in intensity.</p>
<a name="id_be610832-3ba8-43f2-9ccd-ddadb11a4efe"></a><table width="763.000">
<caption><span>Table 4: Postdose Evaluation of Injection-Site Adverse Reactions in Boys and Men 9 Through 26 Years of Age (1 to 5 Days Postvaccination)</span></caption>
<col span="1" width="13.6%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="10.1%">
<col span="1" width="9.3%">
<col span="1" width="8.7%">
<col span="1" width="9.3%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-8">*</a></span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">Saline Placebo</span></p>(% occurrence)</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Adverse</span></p>
<span class="Bold">Reaction</span>
</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N<a href="#footnote-9">†</a> = 3003</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 2898</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 2826</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N = 1950</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 1854</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 1799</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>1</p>N = 269</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>2</p>N = 263</td>
<td>
<p class="First">Post-</p>
<p>dose</p>
<p>3</p>N = 259</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">44.7</p>
<p>44.5</p>0.2</td>
<td>
<p class="First">36.9</p>
<p>36.4</p>0.5</td>
<td>
<p class="First">34.4</p>
<p>34.1</p>0.3</td>
<td>
<p class="First">38.4</p>
<p>37.9</p>0.4</td>
<td>
<p class="First">28.2</p>
<p>28.2</p>0.1</td>
<td>
<p class="First">25.8</p>
<p>25.5</p>0.3</td>
<td>
<p class="First">27.5</p>
<p>27.5</p>0.0</td>
<td>
<p class="First">20.5</p>
<p>20.2</p>0.4</td>
<td>
<p class="First">16.2</p>
<p>16.2</p>0.0</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span></span><a href="#footnote-10">‡</a></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">5.6</p>
<p>5.3</p>0.2</td>
<td>
<p class="First">6.6</p>
<p>6.2</p>0.3</td>
<td>
<p class="First">7.7</p>
<p>7.1</p>0.5</td>
<td>
<p class="First">5.6</p>
<p>5.4</p>0.2</td>
<td>
<p class="First">4.5</p>
<p>4.5</p>0.0</td>
<td>
<p class="First">4.1</p>
<p>4.0</p>0.1</td>
<td>
<p class="First">4.8</p>
<p>4.8</p>0.0</td>
<td>
<p class="First">1.5</p>
<p>1.5</p>0.0</td>
<td>
<p class="First">3.5</p>
<p>3.1</p>0.4</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></span><a href="#footnote-10" class="Sup">10</a></p>
<p>Mild/Moderate</p>Severe</td>
<td>
<p class="First">7.2</p>
<p>6.8</p>0.3</td>
<td>
<p class="First">8.0</p>
<p>7.7</p>0.2</td>
<td>
<p class="First">8.7</p>
<p>8.3</p>0.3</td>
<td>
<p class="First">8.3</p>
<p>8.0</p>0.2</td>
<td>
<p class="First">6.3</p>
<p>6.2</p>0.1</td>
<td>
<p class="First">5.7</p>
<p>5.6</p>0.1</td>
<td>
<p class="First">7.1</p>
<p>7.1</p>0.0</td>
<td>
<p class="First">5.7</p>
<p>5.7</p>0.0</td>
<td>
<p class="First">5.0</p>
<p>5.0</p>0.0</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-8" href="#footnote-8" class="Sup">8</a></p>
<p><a name="footnote-reference-9" href="#footnote-9" class="Sup">9</a></p>
<p><a name="footnote-reference-10" href="#footnote-10" class="Sup">10</a></p>
<p><span class="Italics">Common Systemic Adverse Reactions in Girls and Women 9 Through 26 Years of Age</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was the most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 28.2% and AAHS control or saline placebo = 28.4%). <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> was the next most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 13.0% and AAHS control or saline placebo = 11.2%).</p>
<p>Adverse reactions that were observed among recipients of GARDASIL, at a frequency of greater than or equal to 1.0% where the incidence in the GARDASIL group was greater than or equal to the incidence in the AAHS control or saline placebo group, are shown in Table 5.</p>
<a name="id_5ebdcc2f-e6d4-4a30-bb87-014051b25355"></a><table width="588.000">
<caption><span>Table 5: Common Systemic Adverse Reactions in Girls and Women 9 Through 26 Years of Age (GARDASIL ≥Control)<a href="#footnote-11">*</a></span></caption>
<col span="1" width="43.0%">
<col span="1" width="28.9%">
<col span="1" width="28.1%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">Adverse Reactions</span></p>(1 to 15 Days Postvaccination)</td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>
<p>(N = 5088)</p>%</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-12">†</a> or Saline Placebo</span></p>
<p>(N = 3790)</p>%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td>13.0</td>
<td>11.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td>6.7</td>
<td>6.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td>4.0</td>
<td>3.7</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td>3.6</td>
<td>3.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td>2.4</td>
<td>1.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td>2.0</td>
<td>1.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span></td>
<td>1.5</td>
<td>1.4</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td>1.4</td>
<td>1.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td>1.1</td>
<td>0.9</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-11" href="#footnote-11" class="Sup">11</a></p>
<p><a name="footnote-reference-12" href="#footnote-12" class="Sup">12</a></p>
<p><span class="Italics">Common Systemic Adverse Reactions in Boys and Men 9 Through 26 Years of Age </span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was the most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 12.3% and AAHS control or saline placebo = 11.2%). <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> was the next most commonly reported systemic adverse reaction in both treatment groups (GARDASIL = 8.3% and AAHS control or saline placebo = 6.5%). </p>
<p>Adverse reactions that were observed among recipients of GARDASIL, at a frequency of greater than or equal to 1.0% where the incidence in the group that received GARDASIL was greater than or equal to the incidence in the AAHS control or saline placebo group, are shown in Table 6. </p>
<a name="id_9dd72134-2107-4b4f-bbd4-1a5d1915cad4"></a><table width="588.000">
<caption><span>Table 6: Common Systemic Adverse Reactions in Boys and Men 9 Through 26 Years of Age (GARDASIL ≥Control)<a href="#footnote-13">*</a></span></caption>
<col span="1" width="43.0%">
<col span="1" width="28.9%">
<col span="1" width="28.1%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">Adverse Reactions</span></p>(1 to 15 Days Postvaccination)</td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>
<p>(N = 3093)</p>%</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-14">†</a> or Saline Placebo</span></p>
<p>(N = 2303)</p>%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td>12.3</td>
<td>11.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td>8.3</td>
<td>6.5</td>
</tr>
<tr>
<td>Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td>2.8</td>
<td>2.1</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td>2.7</td>
<td>2.2</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td>2.6</td>
<td>2.6</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td>2.0</td>
<td>1.0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td>1.5</td>
<td>1.0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td>1.4</td>
<td>1.4</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td>1.3</td>
<td>0.7</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td>1.0</td>
<td>0.8</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-13" href="#footnote-13" class="Sup">13</a></p>
<p><a name="footnote-reference-14" href="#footnote-14" class="Sup">14</a></p>
<p><span class="Italics">Evaluation of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> by Dose in Girls and Women 9 Through 26 Years of Age </span></p>
<p>An analysis of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in girls and women by dose is shown in Table 7. </p>
<a name="id_7bc16426-109f-4441-a640-7e2232a0c94c"></a><table width="696.000">
<caption><span>Table 7: Postdose Evaluation of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in Girls and Women 9 Through 26 Years of Age (1 to 5 Days Postvaccination)</span></caption>
<col span="1" width="20.5%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="12.6%">
<col span="1" width="13.4%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-15">*</a> or Saline Placebo</span></p>(% occurrence)</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Temperature</span></p>
<span class="Bold">(°F)</span>
</td>
<td>
<p class="First">Postdose 1</p>N<a href="#footnote-16">†</a> = 4945</td>
<td>
<p class="First">Postdose 2</p>N = 4804</td>
<td>
<p class="First">Postdose 3</p>N = 4671</td>
<td>
<p class="First">Postdose 1</p>N = 3681</td>
<td>
<p class="First">Postdose 2</p>N = 3564</td>
<td>
<p class="First">Postdose 3</p>N = 3467</td>
</tr>
<tr>
<td>≥100 to &lt;102</td>
<td>3.7</td>
<td>4.1</td>
<td>4.4</td>
<td>3.1</td>
<td>3.8</td>
<td>3.6</td>
</tr>
<tr class="Last">
<td>≥102</td>
<td>0.3</td>
<td>0.5</td>
<td>0.5</td>
<td>0.2</td>
<td>0.4</td>
<td>0.5</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-15" href="#footnote-15" class="Sup">15</a></p>
<p><a name="footnote-reference-16" href="#footnote-16" class="Sup">16</a></p>
<p><span class="Italics">Evaluation of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> by Dose in Boys and Men 9 Through 26 Years of Age </span></p>
<p>An analysis of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in boys and men by dose is shown in Table 8. </p>
<a name="id_c6084f03-c966-4cb4-b151-f702b4473d0b"></a><table width="696.000">
<caption><span>Table 8: Postdose Evaluation of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> in Boys and Men 9 Through 26 Years of Age (1 to 5 Days Postvaccination)</span></caption>
<col span="1" width="20.5%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="13.4%">
<col span="1" width="12.6%">
<col span="1" width="13.4%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(% occurrence)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-17">*</a> or Saline Placebo</span></p>(% occurrence)</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold">Temperature</span></p>
<span class="Bold">(°F)</span>
</td>
<td>
<p class="First">Postdose 1</p>N<a href="#footnote-18">†</a> = 2972</td>
<td>
<p class="First">Postdose 2</p>N = 2849</td>
<td>
<p class="First">Postdose 3</p>N = 2792</td>
<td>
<p class="First">Postdose 1</p>N = 2194</td>
<td>
<p class="First">Postdose 2</p>N = 2079</td>
<td>
<p class="First">Postdose 3</p>N = 2046</td>
</tr>
<tr>
<td>≥100 to &lt;102</td>
<td>2.4</td>
<td>2.5</td>
<td>2.3</td>
<td>2.1</td>
<td>2.2</td>
<td>1.6</td>
</tr>
<tr class="Last">
<td>≥102</td>
<td>0.6</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.3</td>
<td>0.3</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-17" href="#footnote-17" class="Sup">17</a></p>
<p><a name="footnote-reference-18" href="#footnote-18" class="Sup">18</a></p>
<p><span class="Italics">Serious Adverse Reactions in the Entire Study Population</span></p>
<p>Across the clinical studies, 258 individuals (GARDASIL N = 128 or 0.8%; placebo N = 130 or 1.0%) out of 29,323 (GARDASIL N = 15,706; AAHS control N = 13,023; or saline placebo N = 594) individuals (9- through 45-year-old girls and women; and 9- through 26-year-old boys and men) reported a serious systemic adverse reaction.</p>
<p>Of the entire study population (29,323 individuals), 0.04% of the reported serious systemic adverse reactions were judged to be vaccine related by the study investigator. The most frequently (frequency of 4 cases or greater with either GARDASIL, AAHS control, saline placebo, or the total of all three) reported serious systemic adverse reactions, regardless of causality, were:</p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> [0.02% GARDASIL (3 cases) vs. 0.02% AAHS control (2 cases)],<br><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span> [0.02% GARDASIL (3 cases) vs. 0.02% AAHS control (2 cases)],<br><span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">Appendicitis</span> [0.03% GARDASIL (5 cases) vs. 0.01% AAHS control (1 case)],<br><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic inflammatory disease</span> [0.02% GARDASIL (3 cases) vs. 0.03% AAHS control (4 cases)],<br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)],<br><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)],<br><span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">Pyelonephritis</span> [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (3 cases)],<br><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)].</p>
<p>One case (0.006% GARDASIL; 0.0% AAHS control or saline placebo) of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>; and 2 cases (0.01% GARDASIL; 0.0% AAHS control or saline placebo) of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were reported as serious systemic adverse reactions that occurred following any vaccination visit.</p>
<p>In addition, there was 1 individual in the clinical trials, in the group that received GARDASIL, who reported two injection-site serious adverse reactions (injection-site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and injection-site joint movement impairment). </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in the Entire Study Population</span></p>
<p>Across the clinical studies, 40 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (GARDASIL N = 21 or 0.1%; placebo N = 19 or 0.1%) were reported in 29,323 (GARDASIL N = 15,706; AAHS control N = 13,023, saline placebo N = 594) individuals (9- through 45-year-old girls and women; and 9- through 26-year-old boys and men). The events reported were consistent with events expected in healthy adolescent and adult populations. The most common cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was <span class="product-label-link" type="condition" conceptid="435134" conceptname="Motor vehicle accident">motor vehicle accident</span> (5 individuals who received GARDASIL and 4 individuals who received AAHS control), followed by drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>/<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> (2 individuals who received GARDASIL and 6 individuals who received AAHS control), gunshot <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> (1 individual who received GARDASIL and 3 individuals who received AAHS control), and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>/<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (1 individual who received GARDASIL and 1 individual who received AAHS control). In addition, there were 2 cases of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, 1 case of pancreatic cancer, 1 case of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, 1 case of <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span>, 1 case of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, 1 case of post-operative <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, 1 case of <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>/<span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, 1 case of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, 1 case of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, 1 case of breast cancer, and 1 case of nasopharyngeal cancer in the group that received GARDASIL; 1 case of <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span>, 1 case of <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span>, 1 case of chemical <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, and 1 case of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in the AAHS control group; and 1 case of <span class="product-label-link" type="condition" conceptid="4306469" conceptname="Medulloblastoma">medulloblastoma</span> in the saline placebo group.</p>
<p><span class="Italics">Systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span> in Girls and Women 9 Through 26 Years of Age</span></p>
<p>In the clinical studies, 9- through 26-year-old girls and women were evaluated for new medical conditions that occurred over the course of follow-up. New medical conditions potentially indicative of a systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorder</span> seen in the group that received GARDASIL or AAHS control or saline placebo are shown in Table 9. This population includes all girls and women who received at least one dose of GARDASIL or AAHS control or saline placebo, and had safety data available.</p>
<a name="id_43526bea-44d1-4a67-b31e-36b5ea7f622c"></a><table width="676.000">
<caption><span>Table 9: Summary of Girls and Women 9 Through 26 Years of Age Who Reported an Incident Condition Potentially Indicative of a Systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorder</span> After Enrollment in Clinical Trials of GARDASIL, Regardless of Causality</span></caption>
<col span="1" width="45.6%">
<col span="1" width="27.7%">
<col span="1" width="26.8%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Conditions</span></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(N = 10,706)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-19">*</a> or Saline Placebo</span></p>(N = 9412)</td>
</tr>
<tr>
<td><span class="Bold">n (%)</span></td>
<td><span class="Bold">n (%)</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>/<span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span><a href="#footnote-20">†</a>
</td>
<td>120 (1.1)</td>
<td>98 (1.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="135215" conceptname="Hashimoto thyroiditis">Autoimmune Thyroiditis</span></td>
<td>4 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td>Celiac Disease</td>
<td>10 (0.1)</td>
<td>6 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Insulin-dependent</td>
<td>2 (0.0)</td>
<td>2 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema Nodosum</span></td>
<td>2 (0.0)</td>
<td>4 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span><a href="#footnote-21">‡</a>
</td>
<td>27 (0.3)</td>
<td>21 (0.2)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span><a href="#footnote-22">§</a>
</td>
<td>35 (0.3)</td>
<td>38 (0.4)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span><a href="#footnote-23">¶</a>
</td>
<td>7 (0.1)</td>
<td>10 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></td>
<td>2 (0.0)</td>
<td>4 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">Nephritis</span><a href="#footnote-24">#</a>
</td>
<td>2 (0.0)</td>
<td>5 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic Neuritis</span></td>
<td>2 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation Disorder</span><a href="#footnote-25">Þ</a>
</td>
<td>4 (0.0)</td>
<td>3 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span><a href="#footnote-26">ß</a>
</td>
<td>13 (0.1)</td>
<td>15 (0.2)</td>
</tr>
<tr>
<td>Raynaud's Phenomenon</td>
<td>3 (0.0)</td>
<td>4 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span><a href="#footnote-27">à</a>
</td>
<td>6 (0.1)</td>
<td>2 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">Scleroderma</span>/Morphea</td>
<td>2 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></td>
<td>1 (0.0)</td>
<td>3 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span></td>
<td>3 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr class="Last">
<td><span class="Bold">All Conditions</span></td>
<td>245 (2.3)</td>
<td>218 (2.3)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-19" href="#footnote-19" class="Sup">19</a></p>
<p><a name="footnote-reference-20" href="#footnote-20" class="Sup">20</a></p>
<p><a name="footnote-reference-21" href="#footnote-21" class="Sup">21</a></p>
<p><a name="footnote-reference-22" href="#footnote-22" class="Sup">22</a></p>
<p><a name="footnote-reference-23" href="#footnote-23" class="Sup">23</a></p>
<p><a name="footnote-reference-24" href="#footnote-24" class="Sup">24</a></p>
<p><a name="footnote-reference-25" href="#footnote-25" class="Sup">25</a></p>
<p><a name="footnote-reference-26" href="#footnote-26" class="Sup">26</a></p>
<p><a name="footnote-reference-27" href="#footnote-27" class="Sup">27</a></p>
<p><span class="Italics">Systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span> in Boys and Men 9 Through 26 Years of Age</span></p>
<p>In the clinical studies, 9- through 26-year-old boys and men were evaluated for new medical conditions that occurred over the course of follow-up. New medical conditions potentially indicative of a systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorder</span> seen in the group that received GARDASIL or AAHS control or saline placebo are shown in Table 10. This population includes all boys and men who received at least one dose of GARDASIL or AAHS control or saline placebo, and had safety data available. </p>
<a name="id_c1eff51b-2d55-4389-986a-572f9590b3f8"></a><table width="675.000">
<caption><span>Table 10: Summary of Boys and Men 9 Through 26 Years of Age Who Reported an Incident Condition Potentially Indicative of a Systemic <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorder</span> After Enrollment in Clinical Trials of GARDASIL, Regardless of Causality</span></caption>
<col span="1" width="46.4%">
<col span="1" width="26.8%">
<col span="1" width="26.8%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Conditions</span></td>
<td>
<p class="First"><span class="Bold">GARDASIL</span></p>(N = 3093)</td>
<td>
<p class="First"><span class="Bold">AAHS Control<a href="#footnote-28">*</a> or Saline Placebo</span></p>(N = 2303)</td>
</tr>
<tr>
<td><span class="Bold">n (%)</span></td>
<td><span class="Bold">n (%)</span></td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="141933" conceptname="Alopecia areata">Alopecia Areata</span></td>
<td>2 (0.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing Spondylitis</span></td>
<td>1 (0.0)</td>
<td>2 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>/Reactive <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></td>
<td>30 (1.0)</td>
<td>17 (0.7)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">Autoimmune Thrombocytopenia</span></td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Type 1</td>
<td>3 (0.1)</td>
<td>2 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></td>
<td>0 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span><a href="#footnote-29">†</a>
</td>
<td>3 (0.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span><a href="#footnote-30">‡</a>
</td>
<td>1 (0.0)</td>
<td>2 (0.1)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span></td>
<td>1 (0.0)</td>
<td>1 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></td>
<td>0 (0.0)</td>
<td>4 (0.2)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4048466" conceptname="Achromia of skin">Skin Depigmentation</span></td>
<td>1 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">Vitiligo</span></td>
<td>2 (0.1)</td>
<td>5 (0.2)</td>
</tr>
<tr class="Last">
<td><span class="Bold">All Conditions</span></td>
<td>46 (1.5)</td>
<td>34 (1.5)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-28" href="#footnote-28" class="Sup">28</a></p>
<p><a name="footnote-reference-29" href="#footnote-29" class="Sup">29</a></p>
<p><a name="footnote-reference-30" href="#footnote-30" class="Sup">30</a></p>
<p><span class="Italics">Safety in Concomitant Use with RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] in Girls and Women 16 Through 23 Years of Age</span></p>
<p>The safety of GARDASIL when administered concomitantly with RECOMBIVAX HB<span class="Sup">®1</span>  [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] was evaluated in an AAHS-controlled study of 1871 girls and women with a mean age of 20.4 years <span class="Italics">[see <a href="#i4i_section_id_b5744b08-3c56-4827-8f39-bea2bd8794d0">Clinical Studies (14.9)</a>]</span>. The race distribution of the study individuals was as follows: 61.6% White; 23.8% Other; 11.9% Black; 1.6% Hispanic (Black and White); 0.8% Asian; and 0.3% American Indian. The rates of systemic and injection-site adverse reactions were similar among girls and women who received concomitant vaccination as compared with those who received GARDASIL or RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)].</p>
<p><span class="Italics">Safety in Concomitant Use with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)] </span></p>
<p>The safety of GARDASIL when administered concomitantly with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)] was evaluated in a randomized study of 1040 boys and girls with a mean age of 12.6 years <span class="Italics">[see <a href="#i4i_section_id_5cd7bcce-5591-43b8-8de6-4725b9f6970e">Clinical Studies (14.10)</a>]</span>. The race distribution of the study subjects was as follows: 77.7% White; 1.4% Multi-racial; 12.3% Black; 6.8% Hispanic (Black and White); 1.2% Asian; 0.4% American Indian, and 0.2% Indian. </p>
<p>There was an increase in injection-site <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> reported at the injection site for GARDASIL (concomitant = 10.9%, non-concomitant = 6.9%) when GARDASIL was administered concomitantly with Menactra and Adacel as compared to non-concomitant (separated by 1 month) vaccination. The majority of injection-site <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> adverse experiences were reported as being mild to moderate in intensity.</p>
<p><span class="Italics">Safety in Women 27 Through 45 Years of Age</span></p>
<p>The adverse reaction profile in women 27 through 45 years of age was comparable to the profile seen in girls and women 9 through 26 years of age.</p>
<p>
 
</p>
<p></p>
<p>The following adverse events have been spontaneously reported during post-approval use of GARDASIL. Because these events were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish a causal relationship to vaccine exposure.</p>
<p>Blood and lymphatic system disorders: <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">Autoimmune hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>. </p>
<p>Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolus</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>General disorders and administration site conditions: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: Autoimmune diseases, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: Acute disseminated <span class="product-label-link" type="condition" conceptid="373189" conceptname="Encephalomyelitis">encephalomyelitis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, Guillain-Barré syndrome, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, motor neuron disease, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (including <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> associated with tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span> and other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-like activity) sometimes resulting in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury, transverse <span class="product-label-link" type="condition" conceptid="138965" conceptname="Myelitis">myelitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>: <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: Deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>The injection-site adverse reactions that were observed among recipients of GARDASIL were at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>The injection-site adverse reactions that were observed among recipients of GARDASIL were at a frequency of at least 1.0% and also at a greater frequency than that observed among AAHS control or saline placebo recipients.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>N = Number of individuals with follow-up</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>Intensity of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> was measured by size (inches): Mild = 0 to ≤1; Moderate = &gt;1 to ≤2; Severe = &gt;2.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">8</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">9</a></dt>
<dd>N = Number of individuals with follow-up</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">10</a></dt>
<dd>Intensity of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> was measured by size (inches): Mild = 0 to ≤1; Moderate = &gt;1 to ≤2; Severe = &gt;2.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">11</a></dt>
<dd>The adverse reactions in this table are those that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than or equal to those observed among AAHS control or saline placebo recipients.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">12</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">13</a></dt>
<dd>The adverse reactions in this table are those that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than or equal to those observed among AAHS control or saline placebo recipients.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">14</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">15</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">16</a></dt>
<dd>N = Number of individuals with follow-up</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">17</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">18</a></dt>
<dd>N = Number of individuals with follow-up</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">19</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">20</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>/<span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> reactive, and <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span></dd>
<dt><a name="footnote-21" href="#footnote-reference-21">21</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> includes the following terms: Basedow's disease, <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span>, Toxic nodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, and <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></dd>
<dt><a name="footnote-22" href="#footnote-reference-22">22</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> and <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></dd>
<dt><a name="footnote-23" href="#footnote-reference-23">23</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory bowel disease</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Colitis ulcerative</span>, Crohn's disease, and <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory bowel disease</span></dd>
<dt><a name="footnote-24" href="#footnote-reference-24">24</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">Nephritis</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">Nephritis</span>, <span class="product-label-link" type="condition" conceptid="4260398" conceptname="Minimal change disease">Glomerulonephritis minimal lesion</span>, <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">Glomerulonephritis</span> proliferative</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">25</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation disorder</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation disorder</span>, <span class="product-label-link" type="condition" conceptid="4048466" conceptname="Achromia of skin">Skin depigmentation</span>, and <span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">Vitiligo</span></dd>
<dt><a name="footnote-26" href="#footnote-reference-26">26</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>, <span class="product-label-link" type="condition" conceptid="4063434" conceptname="Pustular psoriasis">Pustular psoriasis</span>, and Psoriatic <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span></dd>
<dt><a name="footnote-27" href="#footnote-reference-27">27</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span> includes <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>. One woman counted in the <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> group reported <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> as an adverse experience at Day 130.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">28</a></dt>
<dd>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">29</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> and <span class="product-label-link" type="condition" conceptid="135215" conceptname="Hashimoto thyroiditis">Autoimmune thyroiditis</span></dd>
<dt><a name="footnote-30" href="#footnote-reference-30">30</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory bowel disease</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Colitis ulcerative</span> and Crohn's disease</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p>GARDASIL may be administered concomitantly with RECOMBIVAX HB (<a href="#i4i_section_id_031fef78-104b-4101-86be-894086dfac6a">7.1</a>) or with Menactra and Adacel. (<a href="#i4i_section_id_7aa4136d-f34b-4926-95ce-7bae92dcbe7b">7.2</a>)</p>
<p>
 
</p>
<p></p>
<p>Results from clinical studies indicate that GARDASIL may be administered concomitantly (at a separate injection site) with RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] <span class="Italics">[see <a href="#i4i_section_id_b5744b08-3c56-4827-8f39-bea2bd8794d0">Clinical Studies (14.9)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Results from clinical studies indicate that GARDASIL may be administered concomitantly (at a separate injection site) with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)] <span class="Italics">[see <a href="#i4i_section_id_5cd7bcce-5591-43b8-8de6-4725b9f6970e">Clinical Studies (14.10)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>In clinical studies of 16- through 26-year-old women, 13,912 (GARDASIL N = 6952; AAHS control or saline placebo N = 6960) who had post-Month 7 follow-up used hormonal contraceptives for a total of 33,859 person-years (65.8% of the total follow-up time in the studies).</p>
<p>In one clinical study of 24- through 45-year-old women, 1357 (GARDASIL N = 690; AAHS control N = 667) who had post-Month 7 follow-up used hormonal contraceptives for a total of 3400 person-years (31.5% of the total follow-up time in the study). Use of hormonal contraceptives or lack of use of hormonal contraceptives among study participants did not impair the immune response in the per protocol immunogenicity (PPI) population.</p>
<p>
 
</p>
<p></p>
<p>Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines <span class="Italics">[see <a href="#i4i_section_id_99776dde-09fb-4c86-a59d-89e4b56b2b7d">Use in Specific Populations (8.6)</a>]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<p>Safety and effectiveness of GARDASIL have not been established in the following populations:</p>
<ul>
<li>Pregnant women.  Women who receive GARDASIL during pregnancy are encouraged to contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.,at 1-877-888-4231. (<a href="#i4i_pregnancy_id_17349c0e-f548-41b0-9ab9-a0837b233ea9">8.1</a>)</li>
<li>Children below the age of 9 years. (<a href="#i4i_pediatric_use_id_bc41eb42-a681-4606-8302-f92d2d4e9ddd">8.4</a>)</li>
<li>Immunocompromised individuals. Response to GARDASIL may be diminished. (<a href="#i4i_section_id_99776dde-09fb-4c86-a59d-89e4b56b2b7d">8.6</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pregnancy Category B: </span></p>
<p>Reproduction studies have been performed in female rats at doses equivalent to the recommended human dose and have revealed no evidence of impaired female fertility or harm to the fetus due to GARDASIL. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, GARDASIL should be used during pregnancy only if clearly needed. </p>
<p>An evaluation of the effect of GARDASIL on embryo-fetal, pre- and postweaning development was conducted using rats. One group of rats was administered GARDASIL twice prior to gestation, during the period of organogenesis (gestation Day 6) and on lactation Day 7. A second group of pregnant rats was administered GARDASIL during the period of organogenesis (gestation Day 6) and on lactation Day 7 only. GARDASIL was administered at 0.5 mL/rat/occasion (120 mcg total protein which is equivalent to the recommended human dose) by intramuscular injection. No adverse effects on mating, fertility, pregnancy, parturition, lactation, embryo-fetal or pre- and postweaning development were observed. There were no vaccine-related <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> or other evidence of teratogenesis noted in this study. In addition, there were no treatment-related effects on developmental signs, behavior, reproductive performance, or fertility of the offspring. </p>
<p><span class="Italics">Clinical Studies in Humans</span></p>
<p>In clinical studies, women underwent urine pregnancy testing prior to administration of each dose of GARDASIL. Women who were found to be pregnant before completion of a 3-dose regimen of GARDASIL were instructed to defer completion of their vaccination regimen until resolution of the pregnancy. </p>
<p>GARDASIL is not indicated for women 27 years of age or older. However, safety data in women 16 through 45 years of age was collected, and 3819 women (GARDASIL N = 1894 vs. AAHS control or saline placebo N = 1925) reported at least 1 pregnancy each.</p>
<p>The overall proportions of pregnancies that resulted in an adverse outcome, defined as the combined numbers of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, late <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, and <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> cases out of the total number of pregnancy outcomes for which an outcome was known (and excluding elective terminations), were 22.6% (446/1973) in women who received GARDASIL and 23.1% (460/1994) in women who received AAHS control or saline placebo.</p>
<p>Overall, 55 and 65 women in the group that received GARDASIL or AAHS control or saline placebo, respectively (2.9% and 3.4% of all women who reported a pregnancy in the respective vaccination groups), experienced a serious adverse reaction during pregnancy. The most common events reported were conditions that can result in Caesarean section (e.g., failure of labor, malpresentation, cephalopelvic disproportion), premature onset of labor (e.g., <span class="product-label-link" type="condition" conceptid="440457" conceptname="Threatened miscarriage">threatened abortions</span>, <span class="product-label-link" type="condition" conceptid="194702" conceptname="Premature rupture of membranes">premature rupture of membranes</span>), and pregnancy-related medical problems (e.g., pre-<span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>, hyperemesis). The proportions of pregnant women who experienced such events were comparable between the groups receiving GARDASIL and AAHS control or saline placebo.</p>
<p>There were 45 cases of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> in pregnancies that occurred in women who received GARDASIL and 34 cases of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> in pregnancies that occurred in women who received AAHS control or saline placebo.</p>
<p>Further sub-analyses were conducted to evaluate pregnancies with estimated onset within 30 days or more than 30 days from administration of a dose of GARDASIL or AAHS control or saline placebo. For pregnancies with estimated onset within 30 days of vaccination, 5 cases of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> were observed in the group that received GARDASIL compared to 1 case of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> in the group that received AAHS control or saline placebo. The congenital anomalies seen in pregnancies with estimated onset within 30 days of vaccination included <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>, congenital <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="4037874" conceptname="Congenital hydronephrosis">congenital hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="74150" conceptname="Congenital subluxation of hip, bilateral">hip dysplasia</span>, and club foot. Conversely, in pregnancies with onset more than 30 days following vaccination, 40 cases of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> were observed in the group that received GARDASIL compared with 33 cases of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">congenital anomaly</span> in the group that received AAHS control or saline placebo.</p>
<p><span class="Bold">Women who receive GARDASIL during pregnancy are encouraged to contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Women 16 Through 45 Years of Age</span></p>
<p>It is not known whether GARDASIL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GARDASIL is administered to a nursing woman.</p>
<p>GARDASIL or AAHS control were given to a total of 1133 women (vaccine N = 582, AAHS control N = 551) during the relevant Phase III clinical studies.</p>
<p>Overall, 27 and 13 infants of women who received GARDASIL or AAHS control, respectively (representing 4.6% and 2.4% of the total number of women who were breast-feeding during the period in which they received GARDASIL or AAHS control, respectively), experienced a serious adverse reaction.</p>
<p>In a post-hoc analysis of clinical studies, a higher number of breast-feeding infants (n = 7) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post vaccination of the mother as compared to infants (n = 2) whose mothers received AAHS control.</p>
<p>
 
</p>
<p></p>
<p>Safety and effectiveness have not been established in pediatric patients below 9 years of age. </p>
<p>
 
</p>
<p></p>
<p>The safety and effectiveness of GARDASIL have not been evaluated in a geriatric population, defined as individuals aged 65 years and over. </p>
<p>
 
</p>
<p></p>
<p>The immunologic response to GARDASIL may be diminished in immunocompromised individuals <span class="Italics">[see <a href="#i4i_section_id_12f8c7d0-7549-4a54-a2c4-b33c5ce38b83">Drug Interactions (7.4)</a>]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>There have been reports of administration of higher than recommended doses of GARDASIL. </p>
<p>In general, the adverse event profile reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> was comparable to recommended single doses of GARDASIL. </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>GARDASIL, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, is a non-infectious recombinant quadrivalent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1 proteins are produced by separate fermentations in recombinant <span class="Italics">Saccharomyces cerevisiae</span> and self-assembled into VLPs. The fermentation process involves growth of <span class="Italics">S. cerevisiae</span> on chemically-defined fermentation media which include vitamins, amino acids, mineral salts, and carbohydrates. The VLPs are released from the yeast cells by cell disruption and purified by a series of chemical and physical methods. The purified VLPs are adsorbed on preformed aluminum-containing adjuvant (Amorphous Aluminum Hydroxyphosphate Sulfate). The quadrivalent HPV VLP vaccine is a sterile liquid suspension that is prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer.</p>
<p>GARDASIL is a sterile suspension for intramuscular administration. Each 0.5-mL dose contains approximately 20 mcg of HPV 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein.</p>
<p>Each 0.5-mL dose of the vaccine contains approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, &lt;7 mcg yeast protein/dose, and water for injection. The product does not contain a preservative or antibiotics.</p>
<p>After thorough <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, GARDASIL is a white, cloudy liquid.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Human beings develop a humoral immune response to the vaccine, although the exact mechanism of protection is unknown. </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p>GARDASIL has not been evaluated for the potential to cause carcinogenicity or genotoxicity.</p>
<p>GARDASIL administered to female rats at a dose of 120 mcg total protein, which is equivalent to the recommended human dose, had no effects on mating performance, fertility, or embryonic/fetal survival.</p>
<p>The effect of GARDASIL on male fertility has been studied in male rats at an intramuscular dose of 0.5 mL/rat/occasion (120 mcg total protein which is equivalent to the recommended human dose). One group of male rats was administered GARDASIL once, 3 days prior to cohabitation, and a second group of male rats was administered GARDASIL three times, at 6 weeks, 3 weeks, and 3 days prior to cohabitation. There were no treatment-related effects on reproductive performance including fertility, sperm count, and sperm motility. There were no treatment-related gross or histomorphologic and weight changes on the testes.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma of the cervix, respectively. Their detection and removal has been shown to prevent cancer; thus, they serve as surrogate markers for prevention of cervical cancer. In the clinical studies in girls and women aged 16 through 26 years, cases of CIN 2/3 and AIS were the efficacy endpoints to assess prevention of cervical cancer. In addition, cases of VIN 2/3 and VaIN 2/3 were the efficacy endpoints to assess prevention of HPV-related vulvar and vaginal cancers, and observations of external genital lesions were the efficacy endpoints for the prevention of <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>.</p>
<p>In clinical studies in boys and men aged 16 through 26 years, efficacy was evaluated using the following endpoints: external <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> and penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3 or penile/perineal/perianal cancer. In addition, cases of AIN grades 1/2/3 and anal cancer made up the composite efficacy endpoint used to assess prevention of HPV-related anal cancer.</p>
<p>Anal HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, AIN, and anal cancer were not endpoints in the studies conducted in women. The similarity of HPV-related anal disease in men and women supports bridging the indication of prevention of AIN and anal cancer to women.</p>
<p>Efficacy was assessed in 6 AAHS-controlled, double-blind, randomized Phase II and III clinical studies. The first Phase II study evaluated the HPV 16 component of GARDASIL (Study 1, N = 2391 16- through 26-year-old girls and women) and the second evaluated all components of GARDASIL (Study 2, N = 551 16- through 26-year-old girls and women). Two Phase III studies evaluated GARDASIL in 5442 (Study 3) and 12,157 (Study 4) 16- through 26-year-old girls and women. A third Phase III study, Study 5, evaluated GARDASIL in 4055 16- through 26-year-old boys and men, including a subset of 598 (GARDASIL = 299; placebo = 299) men who self-identified as having sex with men (MSM population). A fourth Phase III study, Study 6, evaluated GARDASIL in 3817 24- through 45-year-old women. Together, these six studies evaluated 28,413 individuals (20,541 girls and women 16 through 26 years of age at enrollment with a mean age of 20.0 years, 4055 boys and men 16 through 26 years of age at enrollment with a mean age of 20.5 years, and 3817 women 24 through 45 years of age at enrollment with a mean age of 34.3 years). The race distribution of the 16- through 26-year-old girls and women in the clinical trials was as follows: 70.4% White; 12.2% Hispanic (Black and White); 8.8% Other; 4.6% Black; 3.8% Asian; and 0.2% American Indian. The race distribution of the 16- through 26-year-old boys and men in the clinical trials was as follows: 35.2% White; 20.5% Hispanic (Black and White); 14.4% Other; 19.8% Black; 10.0% Asian; and 0.1% American Indian. The race distribution of the 24- through 45-year-old women in the clinical trials was as follows: 20.6% White; 43.2% Hispanic (Black and White); 0.2% Other; 4.8% Black; 31.2% Asian; and 0.1% American Indian.</p>
<p>The median duration of follow-up was 4.0, 3.0, 3.0, 3.0, 2.3, and 4.0 years for Study 1, Study 2, Study 3, Study 4, Study 5, and Study 6, respectively. Individuals received vaccine or AAHS control on the day of enrollment and 2 and 6 months thereafter. Efficacy was analyzed for each study individually and for all studies in girls and women combined according to a prospective clinical plan.</p>
<p>Overall, 73% of 16- through 26-year-old girls and women, 67% of 24- through 45-year-old women, and 83% of 16- through 26-year-old boys and men were naïve (i.e., PCR [<span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">Polymerase Chain Reaction</span>] negative and seronegative for all 4 vaccine HPV types) to all 4 vaccine HPV types at enrollment.</p>
<p>A total of 27% of 16- through 26-year-old girls and women, 33% of 24- through 45-year-old women, and 17% of 16- through 26-year-old boys and men had evidence of prior exposure to or ongoing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with at least 1 of the 4 vaccine HPV types. Among these individuals, 74% of 16- through 26-year-old girls and women, 71% of 24- through 45-year-old women, and 78% of 16- through 26-year-old boys and men had evidence of prior exposure to or ongoing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with only 1 of the 4 vaccine HPV types and were naïve (PCR negative and seronegative) to the remaining 3 types.</p>
<p>In 24- through 45-year-old individuals, 0.4% had been exposed to all 4 vaccine HPV types. </p>
<p>In individuals who were naïve (PCR negative and seronegative) to all 4 vaccine HPV types, CIN, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, VIN, VaIN, PIN, and persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by any of the 4 vaccine HPV types were counted as endpoints.</p>
<p>Among individuals who were positive (PCR positive and/or seropositive) for a vaccine HPV type at Day 1, endpoints related to that type were not included in the analyses of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy. Endpoints related to the remaining types for which the individual was naïve (PCR negative and seronegative) were counted.</p>
<p>For example, in individuals who were HPV 18 positive (PCR positive and/or seropositive) at Day 1, lesions caused by HPV 18 were not counted in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy evaluations. Lesions caused by HPV 6, 11, and 16 were included in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy evaluations. The same approach was used for the other types.</p>
<p>
 
</p>
<p></p>
<p>GARDASIL was administered without prescreening for presence of HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the efficacy trials allowed enrollment of girls and women regardless of baseline HPV status (i.e., PCR status or serostatus). Girls and women with current or prior HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with an HPV type contained in the vaccine were not eligible for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy evaluations for that type.</p>
<p>The primary analyses of efficacy with respect to HPV types 6, 11, 16, and 18 were conducted in the per-protocol efficacy (PPE) population, consisting of girls and women who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative in cervicovaginal specimens and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy was measured starting after the Month 7 visit.</p>
<p>GARDASIL was efficacious in reducing the incidence of CIN (any grade including CIN 2/3); AIS; <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>; VIN (any grade); and VaIN (any grade) related to vaccine HPV types 6, 11, 16, or 18 in those who were PCR negative and seronegative at baseline (Table 11).</p>
<p>In addition, girls and women who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from precancerous cervical lesions and external genital lesions caused by the other vaccine HPV types.</p>
<a name="id_9c5f1b78-eab6-4816-a9ab-a141b918666d"></a><table width="753.000">
<caption><span>Table 11: Analysis of Efficacy of GARDASIL in the PPE<a href="#footnote-1">*</a> Population<a href="#footnote-2">†</a> of 16- Through 26-Year-Old Girls and Women for Vaccine HPV Types</span></caption>
<col span="1" width="27.8%">
<col span="1" width="7.3%">
<col span="1" width="17.5%">
<col span="1" width="7.3%">
<col span="1" width="18.2%">
<col span="1" width="21.9%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Population</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td><span class="Bold">AAHS Control</span></td>
<td><span class="Bold">% Efficacy (95% CI)</span></td>
</tr>
<tr>
<td>N</td>
<td>Number of cases</td>
<td>N</td>
<td>Number of cases</td>
</tr>
<tr><td><span class="Bold">HPV 16- or 18-related CIN 2/3 or AIS</span></td></tr>
<tr>
<td>Study 1<a href="#footnote-3">‡</a>
</td>
<td>755</td>
<td>0</td>
<td>750</td>
<td>12</td>
<td>100.0 (65.1, 100.0)</td>
</tr>
<tr>
<td>Study 2</td>
<td>231</td>
<td>0</td>
<td>230</td>
<td>1</td>
<td>100.0 (-3744.9, 100.0)</td>
</tr>
<tr>
<td>Study 3</td>
<td>2201</td>
<td>0</td>
<td>2222</td>
<td>36</td>
<td>100.0 (89.2, 100.0)</td>
</tr>
<tr>
<td>Study 4</td>
<td>5306</td>
<td>2</td>
<td>5262</td>
<td>63</td>
<td>96.9 (88.2, 99.6)</td>
</tr>
<tr>
<td>Combined Protocols<a href="#footnote-4">§</a>
</td>
<td>8493</td>
<td>2</td>
<td>8464</td>
<td>112</td>
<td>98.2 (93.5, 99.8)</td>
</tr>
<tr><td><span class="Bold">HPV 16-related CIN 2/3 or AIS</span></td></tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7402</td>
<td>2</td>
<td>7205</td>
<td>93</td>
<td>97.9 (92.3, 99.8)</td>
</tr>
<tr><td><span class="Bold">HPV 18-related CIN 2/3 or AIS</span></td></tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7382</td>
<td>0</td>
<td>7316</td>
<td>29</td>
<td>100.0 (86.6, 100.0)</td>
</tr>
<tr><td><span class="Bold">HPV 16- or 18-related VIN 2/3</span></td></tr>
<tr>
<td>Study 2</td>
<td>231</td>
<td>0</td>
<td>230</td>
<td>0</td>
<td>Not calculated</td>
</tr>
<tr>
<td>Study 3</td>
<td>2219</td>
<td>0</td>
<td>2239</td>
<td>6</td>
<td>100.0 (14.4, 100.0)</td>
</tr>
<tr>
<td>Study 4</td>
<td>5322</td>
<td>0</td>
<td>5275</td>
<td>4</td>
<td>100.0 (-50.3, 100.0)</td>
</tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7772</td>
<td>0</td>
<td>7744</td>
<td>10</td>
<td>100.0 (55.5, 100.0)</td>
</tr>
<tr><td><span class="Bold">HPV 16- or 18-related VaIN 2/3</span></td></tr>
<tr>
<td>Study 2</td>
<td>231</td>
<td>0</td>
<td>230</td>
<td>0</td>
<td>Not calculated</td>
</tr>
<tr>
<td>Study 3</td>
<td>2219</td>
<td>0</td>
<td>2239</td>
<td>5</td>
<td>100.0 (-10.1, 100.0)</td>
</tr>
<tr>
<td>Study 4</td>
<td>5322</td>
<td>0</td>
<td>5275</td>
<td>4</td>
<td>100.0 (-50.3, 100.0)</td>
</tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7772</td>
<td>0</td>
<td>7744</td>
<td>9</td>
<td>100.0 (49.5, 100.0)</td>
</tr>
<tr><td><span class="Bold">HPV 6-, 11-, 16-, or 18-related CIN (CIN 1, CIN 2/3) or AIS</span></td></tr>
<tr>
<td>Study 2</td>
<td>235</td>
<td>0</td>
<td>233</td>
<td>3</td>
<td>100.0 (-138.4, 100.0)</td>
</tr>
<tr>
<td>Study 3</td>
<td>2241</td>
<td>0</td>
<td>2258</td>
<td>77</td>
<td>100.0 (95.1, 100.0)</td>
</tr>
<tr>
<td>Study 4</td>
<td>5388</td>
<td>9</td>
<td>5374</td>
<td>145</td>
<td>93.8 (88.0, 97.2)</td>
</tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7864</td>
<td>9</td>
<td>7865</td>
<td>225</td>
<td>96.0 (92.3, 98.2)</td>
</tr>
<tr><td><span class="Bold">HPV 6-, 11-, 16-, or 18-related <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></span></td></tr>
<tr>
<td>Study 2</td>
<td>235</td>
<td>0</td>
<td>233</td>
<td>3</td>
<td>100.0 (-139.5, 100.0)</td>
</tr>
<tr>
<td>Study 3</td>
<td>2261</td>
<td>0</td>
<td>2279</td>
<td>58</td>
<td>100.0 (93.5, 100.0)</td>
</tr>
<tr>
<td>Study 4</td>
<td>5404</td>
<td>2</td>
<td>5390</td>
<td>132</td>
<td>98.5 (94.5, 99.8)</td>
</tr>
<tr>
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>7900</td>
<td>2</td>
<td>7902</td>
<td>193</td>
<td>99.0 (96.2, 99.9)</td>
</tr>
<tr><td><span class="Bold">HPV 6- and 11-related <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></span></td></tr>
<tr class="Last">
<td>Combined Protocols<a href="#footnote-34" class="Sup">34</a>
</td>
<td>6932</td>
<td>2</td>
<td>6856</td>
<td>189</td>
<td>99.0 (96.2, 99.9)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-31" href="#footnote-31" class="Sup">31</a></p>
<p><a name="footnote-reference-32" href="#footnote-32" class="Sup">32</a></p>
<p><a name="footnote-reference-33" href="#footnote-33" class="Sup">33</a></p>
<p><a name="footnote-reference-34" href="#footnote-34" class="Sup">34</a></p>
<p><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> efficacy against overall cervical and genital disease related to HPV 6, 11, 16, and 18 in an extension phase of Study 2, that included data through Month 60, was noted to be 100% (95% CI: 12.3%, 100.0%) among girls and women in the per protocol population naïve to the relevant HPV types. </p>
<p>GARDASIL was efficacious against HPV disease caused by HPV types 6, 11, 16, and 18 in girls and women who were naïve for those specific HPV types at baseline.</p>
<p>
 
</p>
<p></p>
<p>The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population. This population consisted of boys and men who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (Month 7). Efficacy was measured starting after the Month 7 visit.</p>
<p>GARDASIL was efficacious in reducing the incidence of <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> related to vaccine HPV types 6 and 11 in those boys and men who were PCR negative and seronegative at baseline (Table 12). Efficacy against penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3 or penile/perineal/perianal cancer was not demonstrated as the number of cases was too limited to reach statistical significance.</p>
<a name="id_e5c0d10e-48c8-4b68-851d-580e65904463"></a><table width="719.000">
<caption><span>Table 12: Analysis of Efficacy of GARDASIL in the PPE<a href="#footnote-1">*</a> Population of 16- Through 26-Year-Old Boys and Men for Vaccine HPV Types</span></caption>
<col span="1" width="28.2%">
<col span="1" width="9.2%">
<col span="1" width="16.0%">
<col span="1" width="9.2%">
<col span="1" width="16.8%">
<col span="1" width="20.6%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoint</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td><span class="Bold">AAHS Control</span></td>
<td><span class="Bold">% Efficacy (95% CI)</span></td>
</tr>
<tr>
<td>N<a href="#footnote-2">†</a>
</td>
<td>Number of cases</td>
<td>N</td>
<td>Number of cases</td>
</tr>
<tr><td><span class="Bold">External Genital Lesions HPV 6-, 11-, 16-, or 18- related</span></td></tr>
<tr>
<td>External Genital Lesions</td>
<td>1394</td>
<td>3</td>
<td>1404</td>
<td>32</td>
<td>90.6 (70.1, 98.2)</td>
</tr>
<tr>
<td>Condyloma </td>
<td>1394</td>
<td>3</td>
<td>1404</td>
<td>28</td>
<td>89.3 (65.3, 97.9)</td>
</tr>
<tr>
<td>PIN 1/2/3</td>
<td>1394</td>
<td>0</td>
<td>1404</td>
<td>4</td>
<td>100.0 (-52.1, 100.0)</td>
</tr>
<tr class="Last"><td>CI = Confidence Interval<br>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</td></tr>
</tbody>
</table>
<p><a name="footnote-reference-35" href="#footnote-35" class="Sup">35</a></p>
<p><a name="footnote-reference-36" href="#footnote-36" class="Sup">36</a></p>
<p>
 
</p>
<p></p>
<p>A sub-study of Study 5 evaluated the efficacy of GARDASIL against anal disease (anal intraepithelial neoplasia and anal cancer) in a population of 598 MSM. The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population of Study 5. </p>
<p>GARDASIL was efficacious in reducing the incidence of anal intraepithelial neoplasia (AIN) grades 1 (both condyloma and non-acuminate), 2, and 3 related to vaccine HPV types 6, 11, 16, and 18 in those boys and men who were PCR negative and seronegative at baseline (Table 13). </p>
<a name="id_81e919d7-d572-47b6-bc48-abdc4f6d5b08"></a><table width="756.000">
<caption><span>Table 13: Analysis of Efficacy of GARDASIL for Anal Disease in the PPE<a href="#footnote-1">*</a> Population of 16- Through 26-Year-Old Boys and Men in the MSM Sub-study for Vaccine HPV Types</span></caption>
<col span="1" width="26.2%">
<col span="1" width="8.7%">
<col span="1" width="16.0%">
<col span="1" width="7.9%">
<col span="1" width="16.0%">
<col span="1" width="25.1%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">HPV 6-, 11-, 16-, or 18- related Endpoint</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td><span class="Bold">AAHS Control</span></td>
<td><span class="Bold">% Efficacy (95% CI)</span></td>
</tr>
<tr>
<td>N<a href="#footnote-2">†</a>
</td>
<td>Number of cases</td>
<td>N</td>
<td>Number of cases</td>
</tr>
<tr>
<td>AIN 1/2/3</td>
<td>194</td>
<td>5</td>
<td>208</td>
<td>24</td>
<td>77.5 (39.6, 93.3)</td>
</tr>
<tr>
<td>AIN 2/3</td>
<td>194</td>
<td>3</td>
<td>208</td>
<td>13</td>
<td>74.9 (8.8, 95.4)</td>
</tr>
<tr>
<td>AIN 1<br>   <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Condyloma Acuminatum</span><br>   Non-acuminate</td>
<td>194<br>194<br>194</td>
<td>4<br>0<br>4</td>
<td>208<br>208<br>208</td>
<td>16<br>6<br>11</td>
<td>73.0 (16.3, 93.4)<br>100.0 (8.2, 100.0)<br>60.4 (-33.5, 90.8)</td>
</tr>
<tr><td>CI = Confidence Interval<br>AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate</td></tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-37" href="#footnote-37" class="Sup">37</a></p>
<p><a name="footnote-reference-38" href="#footnote-38" class="Sup">38</a></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types </span></p>
<p>The clinical trials included girls and women regardless of current or prior exposure to vaccine HPV types, and additional analyses were conducted to evaluate the impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related cervical and genital disease in these girls and women. Here, analyses included events arising among girls and women regardless of baseline PCR status and serostatus, including HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were present at the start of vaccination as well as events that arose from <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were acquired after the start of vaccination.</p>
<p>The impact of GARDASIL in girls and women regardless of current or prior exposure to a vaccine HPV type is shown in Table 14. Impact was measured starting 1 month Postdose 1. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> efficacy denotes the vaccine's efficacy in girls and women who are naïve (PCR negative and seronegative) to the relevant HPV types at Day 1. Vaccine impact in girls and women who were positive for vaccine HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, as well as vaccine impact among girls and women regardless of baseline vaccine HPV PCR status and serostatus are also presented. The majority of CIN and <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, VIN, and VaIN related to a vaccine HPV type detected in the group that received GARDASIL occurred as a consequence of HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with the relevant HPV type that was already present at Day 1.</p>
<p>There was no clear evidence of protection from disease caused by HPV types for which girls and women were PCR positive regardless of serostatus at baseline.</p>
<a name="id_faf9dd06-9e45-48ad-9e01-a87ffea69999"></a><table width="740.000">
<caption><span>Table 14: Effectiveness of GARDASIL in Prevention of HPV 6, 11, 16, or 18-Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types</span></caption>
<col span="1" width="14.1%">
<col span="1" width="33.4%">
<col span="1" width="8.1%">
<col span="1" width="8.9%">
<col span="1" width="8.1%">
<col span="1" width="9.6%">
<col span="1" width="17.8%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoint</span></td>
<td><span class="Bold">Analysis</span></td>
<td><span class="Bold">GARDASIL or HPV 16 L1 VLP Vaccine</span></td>
<td><span class="Bold">AAHS Control</span></td>
<td><span class="Bold">% Reduction <br>(95% CI)</span></td>
</tr>
<tr>
<td>N</td>
<td>Cases</td>
<td>N</td>
<td>Cases</td>
</tr>
<tr>
<td>HPV 16- or 18-related CIN 2/3 or AIS</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-1">*</a>
</td>
<td>9346</td>
<td>4</td>
<td>9407</td>
<td>155</td>
<td>97.4 (93.3, 99.3)</td>
</tr>
<tr>
<td>HPV 16 and/or HPV 18 Positive at Day 1<a href="#footnote-2">†</a>
</td>
<td>2870</td>
<td>142</td>
<td>2898</td>
<td>148<a href="#footnote-3">‡</a>
</td>
<td>
<span class="Bold">--</span><a href="#footnote-4">§</a>
</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18<a href="#footnote-5">¶</a>
</td>
<td>9836</td>
<td>146</td>
<td>9904</td>
<td>303</td>
<td>51.8 (41.1, 60.7) </td>
</tr>
<tr>
<td>HPV 16- or 18-related VIN 2/3 or VaIN 2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-39" class="Sup">39</a>
</td>
<td>8642</td>
<td>1</td>
<td>8673</td>
<td>34</td>
<td>97.0 (82.4, 99.9)</td>
</tr>
<tr>
<td>HPV 16 and/or HPV 18 Positive at Day 1<a href="#footnote-40" class="Sup">40</a>
</td>
<td>1880</td>
<td>8</td>
<td>1876</td>
<td>4</td>
<td>
<span class="Bold">--</span><a href="#footnote-42" class="Sup">42</a>
</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18<a href="#footnote-43" class="Sup">43</a>
</td>
<td>8955</td>
<td>9</td>
<td>8968</td>
<td>38</td>
<td>76.3 (50.0, 89.9) </td>
</tr>
<tr>
<td>HPV 6-, 11-, 16-, 18-related CIN (CIN 1, CIN 2/3) or AIS</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-39" class="Sup">39</a>
</td>
<td>8630</td>
<td>16</td>
<td>8680</td>
<td>309</td>
<td>94.8 (91.5, 97.1)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-40" class="Sup">40</a>
</td>
<td>2466</td>
<td>186<a href="#footnote-6">#</a>
</td>
<td>2437</td>
<td>213<a href="#footnote-44" class="Sup">44</a>
</td>
<td>
<span class="Bold">--</span><a href="#footnote-42" class="Sup">42</a>
</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types<a href="#footnote-43" class="Sup">43</a>
</td>
<td>8819</td>
<td>202</td>
<td>8854</td>
<td>522</td>
<td>61.5 (54.6, 67.4) </td>
</tr>
<tr>
<td>HPV 6-, 11-, 16-, or 18-related <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-39" class="Sup">39</a>
</td>
<td>8761</td>
<td>10</td>
<td>8792</td>
<td>252</td>
<td>96.0 (92.6, 98.1)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-40" class="Sup">40</a>
</td>
<td>2501</td>
<td>51<a href="#footnote-7">Þ</a>
</td>
<td>2475</td>
<td>55<a href="#footnote-45" class="Sup">45</a>
</td>
<td>
<span class="Bold">--</span><a href="#footnote-42" class="Sup">42</a>
</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types<a href="#footnote-43" class="Sup">43</a>
</td>
<td>8955</td>
<td>61</td>
<td>8968</td>
<td>307</td>
<td>80.3 (73.9, 85.3) </td>
</tr>
<tr>
<td>HPV 6- or 11-related <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-39" class="Sup">39</a>
</td>
<td>7769</td>
<td>9</td>
<td>7792</td>
<td>246</td>
<td>96.4 (93.0, 98.4)</td>
</tr>
<tr>
<td>HPV 6 and/or HPV 11 Positive at Day 1<a href="#footnote-40" class="Sup">40</a>
</td>
<td>1186</td>
<td>51</td>
<td>1176</td>
<td>54</td>
<td>
<span class="Bold">--</span><a href="#footnote-42" class="Sup">42</a>
</td>
</tr>
<tr class="Last">
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types<a href="#footnote-43" class="Sup">43</a>
</td>
<td>8955</td>
<td>60</td>
<td>8968</td>
<td>300</td>
<td>80.1 (73.7, 85.2) </td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-39" href="#footnote-39" class="Sup">39</a></p>
<p><a name="footnote-reference-40" href="#footnote-40" class="Sup">40</a></p>
<p><a name="footnote-reference-41" href="#footnote-41" class="Sup">41</a></p>
<p><a name="footnote-reference-42" href="#footnote-42" class="Sup">42</a></p>
<p><a name="footnote-reference-43" href="#footnote-43" class="Sup">43</a></p>
<p><a name="footnote-reference-44" href="#footnote-44" class="Sup">44</a></p>
<p><a name="footnote-reference-45" href="#footnote-45" class="Sup">45</a></p>
<p><span class="Italics">Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with Vaccine or Non-Vaccine HPV Types </span></p>
<p>The impact of GARDASIL against the overall burden of dysplastic or papillomatous cervical, vulvar, and vaginal disease regardless of HPV detection, results from a combination of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy against vaccine HPV types, disease contribution from vaccine HPV types present at time of vaccination, the disease contribution from HPV types not contained in the vaccine, and disease in which HPV was not detected.</p>
<p>Additional efficacy analyses were conducted in 2 populations: (1) a generally HPV-naïve population (negative to 14 common HPV types and had a Pap test that was negative for SIL [Squamous Intraepithelial Lesion] at Day 1), approximating a population of sexually-naïve girls and women and (2) the general study population of girls and women regardless of baseline HPV status, some of whom had HPV-related disease at Day 1.</p>
<p>Among generally HPV-naïve girls and women and among all girls and women in the study population (including girls and women with HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at Day 1), GARDASIL reduced the overall incidence of CIN 2/3 or AIS; of VIN 2/3 or VaIN 2/3; of CIN (any grade) or AIS; and of <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span> (Table 15). These reductions were primarily due to reductions in lesions caused by HPV types 6, 11, 16, and 18 in girls and women naïve (seronegative and PCR negative) for the specific relevant vaccine HPV type. Infected girls and women may already have CIN 2/3 or AIS at Day 1 and some will develop CIN 2/3 or AIS during follow-up, either related to a vaccine or non-vaccine HPV type present at the time of vaccination or related to a non-vaccine HPV type not present at the time of vaccination.</p>
<a name="id_09f8cc5a-8c57-42c9-b8bc-3e6322c4c3fa"></a><table width="745.000">
<caption><span>Table 15: Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with Vaccine or Non-Vaccine HPV Types</span></caption>
<col span="1" width="21.3%">
<col span="1" width="31.7%">
<col span="1" width="6.6%">
<col span="1" width="8.1%">
<col span="1" width="6.6%">
<col span="1" width="8.1%">
<col span="1" width="17.7%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoints Caused by Vaccine or Non-vaccine HPV Types</span></td>
<td><span class="Bold">Analysis</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td><span class="Bold">AAHS Control</span></td>
<td><span class="Bold">% Reduction <br>(95% CI)</span></td>
</tr>
<tr>
<td>N</td>
<td>Cases</td>
<td>N</td>
<td>Cases</td>
</tr>
<tr>
<td>CIN 2/3 or AIS</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-8">*</a>
</td>
<td>4616</td>
<td>77</td>
<td>4680</td>
<td>136</td>
<td>42.7 (23.7, 57.3)</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-9">†</a>
</td>
<td>8559</td>
<td>421</td>
<td>8592</td>
<td>516</td>
<td>18.4 (7.0, 28.4) </td>
</tr>
<tr>
<td>VIN 2/3 and VaIN 2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-46" class="Sup">46</a>
</td>
<td>4688</td>
<td>7</td>
<td>4735</td>
<td>31</td>
<td>77.1 (47.1, 91.5)</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-47" class="Sup">47</a>
</td>
<td>8688</td>
<td>30</td>
<td>8701</td>
<td>61</td>
<td>50.7 (22.5, 69.3) </td>
</tr>
<tr>
<td>CIN (Any Grade) or AIS</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-46" class="Sup">46</a>
</td>
<td>4616</td>
<td>272</td>
<td>4680</td>
<td>390</td>
<td>29.7 (17.7, 40.0)</td>
</tr>
<tr>
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-47" class="Sup">47</a>
</td>
<td>8559</td>
<td>967</td>
<td>8592</td>
<td>1189</td>
<td>19.1 (11.9, 25.8) </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital Warts</span></td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-46" class="Sup">46</a>
</td>
<td>4688</td>
<td>29</td>
<td>4735</td>
<td>169</td>
<td>82.8 (74.3, 88.8)</td>
</tr>
<tr class="Last">
<td>Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-47" class="Sup">47</a>
</td>
<td>8688</td>
<td>132</td>
<td>8701</td>
<td>350</td>
<td>62.5 (54.0, 69.5) </td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-46" href="#footnote-46" class="Sup">46</a></p>
<p><a name="footnote-reference-47" href="#footnote-47" class="Sup">47</a></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Anogenital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types </span></p>
<p>Study 5 included boys and men regardless of current or prior exposure to vaccine HPV types, and additional analyses were conducted to evaluate the impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related anogenital disease in these boys and men. Here, analyses included events arising among boys and men regardless of baseline PCR status and serostatus, including HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were present at the start of vaccination as well as events that arose from <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were acquired after the start of vaccination.</p>
<p>The impact of GARDASIL in boys and men regardless of current or prior exposure to a vaccine HPV type is shown in Table 16. Impact was measured starting at Day 1. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> efficacy denotes the vaccine's efficacy in boys and men who are naïve (PCR negative and seronegative) to the relevant HPV types at Day 1. Vaccine impact in boys and men who were positive for vaccine HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, as well as vaccine impact among boys and men regardless of baseline vaccine HPV PCR status and serostatus are also presented. The majority of anogenital disease related to a vaccine HPV type detected in the group that received GARDASIL occurred as a consequence of HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with the relevant HPV type that was already present at Day 1. </p>
<p>There was no clear evidence of protection from disease caused by HPV types for which boys and men were PCR positive regardless of serostatus at baseline.</p>
<a name="id_4abcfda1-cf03-4d61-8e13-6e5163c143a2"></a><table width="729.000">
<caption><span>Table 16: Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Anogenital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types</span></caption>
<col span="1" width="11.2%">
<col span="1" width="33.9%">
<col span="1" width="8.2%">
<col span="1" width="9.1%">
<col span="1" width="8.2%">
<col span="1" width="9.1%">
<col span="1" width="20.3%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoint</span></td>
<td><span class="Bold">Analysis</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td>
<p class="First"><span class="Bold">AAHS </span></p>
<span class="Bold">Control</span>
</td>
<td>
<p class="First"><span class="Bold">% Reduction </span></p>
<span class="Bold">(95% CI)</span>
</td>
</tr>
<tr>
<td>N</td>
<td>Cases</td>
<td>N</td>
<td>Cases</td>
</tr>
<tr>
<td>External Genital Lesions</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-1">*</a>
</td>
<td>1775</td>
<td>13</td>
<td>1770</td>
<td>54</td>
<td>76.3 (56.0, 88.1)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-2">†</a>
</td>
<td>460</td>
<td>14</td>
<td>453</td>
<td>26</td>
<td>
<span class="Bold">--</span><a href="#footnote-3">‡</a>
</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-4">§</a>
</td>
<td>1943</td>
<td>27</td>
<td>1937</td>
<td>80</td>
<td>66.7 (48.0, 79.3) </td>
</tr>
<tr>
<td>Condyloma</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-48" class="Sup">48</a>
</td>
<td>1775</td>
<td>10</td>
<td>1770</td>
<td>49</td>
<td>80.0 (59.9, 90.9)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-49" class="Sup">49</a>
</td>
<td>460</td>
<td>14</td>
<td>453</td>
<td>25</td>
<td>
<span class="Bold">--</span><a href="#footnote-50" class="Sup">50</a>
</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-51" class="Sup">51</a>
</td>
<td>1943</td>
<td>24</td>
<td>1937</td>
<td>74</td>
<td>68.1 (48.8, 80.7) </td>
</tr>
<tr>
<td>PIN 1/2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-48" class="Sup">48</a>
</td>
<td>1775</td>
<td>4</td>
<td>1770</td>
<td>5</td>
<td>20.7 (-268.4, 84.3)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-49" class="Sup">49</a>
</td>
<td>460</td>
<td>2</td>
<td>453</td>
<td>1</td>
<td>
<span class="Bold">--</span><a href="#footnote-50" class="Sup">50</a>
</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-51" class="Sup">51</a>
</td>
<td>1943</td>
<td>6</td>
<td>1937</td>
<td>6</td>
<td>0.3 (-272.8, 73.4) </td>
</tr>
<tr>
<td>AIN 1/2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-48" class="Sup">48</a>
</td>
<td>259</td>
<td>9</td>
<td>261</td>
<td>39</td>
<td>76.9 (51.4, 90.1)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-49" class="Sup">49</a>
</td>
<td>103</td>
<td>29</td>
<td>116</td>
<td>38</td>
<td>
<span class="Bold">--</span><a href="#footnote-50" class="Sup">50</a>
</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-51" class="Sup">51</a>
</td>
<td>275</td>
<td>38</td>
<td>276</td>
<td>77</td>
<td>50.3 (25.7, 67.2)</td>
</tr>
<tr>
<td>AIN 2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-48" class="Sup">48</a>
</td>
<td>259</td>
<td>7</td>
<td>261</td>
<td>19</td>
<td>62.5 (6.9, 86.7)</td>
</tr>
<tr>
<td>HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1<a href="#footnote-49" class="Sup">49</a>
</td>
<td>103</td>
<td>11</td>
<td>116</td>
<td>20</td>
<td>
<span class="Bold">--</span><a href="#footnote-50" class="Sup">50</a>
</td>
</tr>
<tr class="Last">
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-51" class="Sup">51</a>
</td>
<td>275</td>
<td>18</td>
<td>276</td>
<td>39</td>
<td>54.2 (18.0, 75.3)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-48" href="#footnote-48" class="Sup">48</a></p>
<p><a name="footnote-reference-49" href="#footnote-49" class="Sup">49</a></p>
<p><a name="footnote-reference-50" href="#footnote-50" class="Sup">50</a></p>
<p><a name="footnote-reference-51" href="#footnote-51" class="Sup">51</a></p>
<p><span class="Italics">Effectiveness of GARDASIL in Prevention of Any HPV Type Related Anogenital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with Vaccine or Non-Vaccine HPV Types </span></p>
<p>The impact of GARDASIL against the overall burden of dysplastic or papillomatous anogenital disease regardless of HPV detection, results from a combination of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> efficacy against vaccine HPV types, disease contribution from vaccine HPV types present at time of vaccination, the disease contribution from HPV types not contained in the vaccine, and disease in which HPV was not detected. </p>
<p>Additional efficacy analyses from Study 5 were conducted in 2 populations: (1) a generally HPV-naïve population that consisted of boys and men who are seronegative and PCR negative to HPV 6, 11, 16, and 18 and PCR negative to HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 at Day 1, approximating a population of sexually-naïve boys and men and (2) the general study population of boys and men regardless of baseline HPV status, some of whom had HPV-related disease at Day 1.</p>
<p>Among generally HPV-naïve boys and men and among all boys and men in Study 5 (including boys and men with HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at Day 1), GARDASIL reduced the overall incidence of anogenital disease (Table 17). These reductions were primarily due to reductions in lesions caused by HPV types 6, 11, 16, and 18 in boys and men naïve (seronegative and PCR negative) for the specific relevant vaccine HPV type. Infected boys and men may already have anogenital disease at Day 1 and some will develop anogenital disease during follow-up, either related to a vaccine or non-vaccine HPV type present at the time of vaccination or related to a non-vaccine HPV type not present at the time of vaccination.</p>
<a name="id_331ed961-c412-4067-8b1e-b69e3225289f"></a><table width="730.000">
<caption><span>Table 17: Effectiveness of GARDASIL in Prevention of Any HPV Type Related Anogenital Disease in Boys and Men 16 Through 26 Years of Age, Regardless of Current or Prior <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with Vaccine or Non-Vaccine HPV Types</span></caption>
<col span="1" width="12.7%">
<col span="1" width="33.8%">
<col span="1" width="7.5%">
<col span="1" width="9.0%">
<col span="1" width="8.2%">
<col span="1" width="9.0%">
<col span="1" width="19.6%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Endpoint</span></td>
<td><span class="Bold">Analysis</span></td>
<td><span class="Bold">GARDASIL</span></td>
<td>
<p class="First"><span class="Bold">AAHS </span></p>
<span class="Bold">Control</span>
</td>
<td><span class="Bold">% Reduction (95% CI)</span></td>
</tr>
<tr>
<td>N</td>
<td>Cases</td>
<td>N</td>
<td>Cases</td>
</tr>
<tr>
<td>External Genital Lesions</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-5">*</a>
</td>
<td>1275</td>
<td>7</td>
<td>1270</td>
<td>37</td>
<td>81.5 (58.0, 93.0)</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-6">†</a>
</td>
<td>1943</td>
<td>38</td>
<td>1937</td>
<td>92</td>
<td>59.3 (40.0, 72.9) </td>
</tr>
<tr>
<td>Condyloma</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-52" class="Sup">52</a>
</td>
<td>1275</td>
<td>5</td>
<td>1270</td>
<td>33</td>
<td>85.2 (61.8, 95.5)</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-53" class="Sup">53</a>
</td>
<td>1943</td>
<td>33</td>
<td>1937</td>
<td>85</td>
<td>61.8 (42.3, 75.3) </td>
</tr>
<tr>
<td>PIN 1/2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-52" class="Sup">52</a>
</td>
<td>1275</td>
<td>2</td>
<td>1270</td>
<td>4</td>
<td>50.7 (-244.3, 95.5)</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-53" class="Sup">53</a>
</td>
<td>1943</td>
<td>8</td>
<td>1937</td>
<td>7</td>
<td>-13.9 (-269.0, 63.9) </td>
</tr>
<tr>
<td>AIN 1/2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-52" class="Sup">52</a>
</td>
<td>129</td>
<td>12</td>
<td>126</td>
<td>28</td>
<td>54.9 (8.4, 79.1)</td>
</tr>
<tr>
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-53" class="Sup">53</a>
</td>
<td>275</td>
<td>74</td>
<td>276</td>
<td>103</td>
<td>25.7 (-1.1, 45.6)</td>
</tr>
<tr>
<td>AIN 2/3</td>
<td><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Efficacy<a href="#footnote-52" class="Sup">52</a>
</td>
<td>129</td>
<td>8</td>
<td>126</td>
<td>18</td>
<td>52.5 (-14.8, 82.1)</td>
</tr>
<tr class="Last">
<td>Boys and Men Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types<a href="#footnote-53" class="Sup">53</a>
</td>
<td>275</td>
<td>44</td>
<td>276</td>
<td>59</td>
<td>24.3 (-13.8, 50.0)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-52" href="#footnote-52" class="Sup">52</a></p>
<p><a name="footnote-reference-53" href="#footnote-53" class="Sup">53</a></p>
<p>
 
</p>
<p></p>
<p>The subject characteristics (e.g. lifetime sex partners, geographic distribution of the subjects) influence the HPV prevalence of the population and therefore the population benefit can vary widely.</p>
<p>The overall efficacy of GARDASIL will vary with the baseline prevalence of HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and disease, the incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> against which GARDASIL has shown protection, and those <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> against which GARDASIL has not been shown to protect.</p>
<p>The efficacy of GARDASIL for HPV types not included in the vaccine (i.e., cross-protective efficacy) is a component of the overall impact of the vaccine on rates of disease caused by HPV. Cross-protective efficacy was not demonstrated against disease caused by non-vaccine HPV types in the combined database of the Study 3 and Study 4 trials.</p>
<p>GARDASIL does not protect against genital disease not related to HPV. One woman who received GARDASIL in Study 3 developed an external genital well-differentiated squamous cell carcinoma at Month 24. No HPV DNA was detected in the lesion or in any other samples taken throughout the study.</p>
<p>In 18,150 girls and women enrolled in Study 2, Study 3, and Study 4, GARDASIL reduced definitive cervical therapy procedures by 23.9% (95% CI: 15.2%, 31.7%). </p>
<p>
 
</p>
<p></p>
<p>Study 6 evaluated efficacy in 3253 women 27 through 45 years of age based on a combined endpoint of HPV 6-, 11-, 16- or 18-related persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, vulvar and vaginal dysplastic lesions of any grade, CIN of any grade, AIS, and cervical cancer. These women were randomized 1:1 to receive either GARDASIL or AAHS control. The efficacy for the combined endpoint was driven primarily by prevention of persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. There was no statistically significant efficacy demonstrated for CIN 2/3, AIS, or cervical cancer. In post hoc analyses conducted to assess the impact of GARDASIL on the individual components of the combined endpoint, the results in the population of women naïve to the relevant HPV type at baseline were as follows: prevention of HPV 6-, 11-, 16- or 18-related persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (80.5% [95% CI: 68.3, 88.6]), prevention of HPV 6-, 11-, 16- or 18-related CIN (any grade) (85.8% [95% CI: 52.4, 97.3]), and prevention of HPV 6-, 11-, 16- or 18-related <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> (87.6% [95% CI: 7.3, 99.7]).</p>
<p>Efficacy for disease endpoints was diminished in a population impact assessment of women who were vaccinated regardless of baseline HPV status (full analysis set). In the full analysis set (FAS), efficacy was not demonstrated for the following endpoints: prevention of HPV 16- and 18-related CIN 2/3, AIS, or cervical cancer and prevention of HPV 6- and 11-related condyloma. No efficacy was demonstrated against CIN 2/3, AIS, or cervical cancer in the general population irrespective of HPV type (FAS any type analysis).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Assays to Measure Immune Response</span></p>
<p>The minimum anti-HPV titer that confers protective efficacy has not been determined.</p>
<p>Because there were few disease cases in individuals naïve (PCR negative and seronegative) to vaccine HPV types at baseline in the group that received GARDASIL, it has not been possible to establish minimum anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 antibody levels that protect against clinical disease caused by HPV 6, 11, 16, and/or 18.</p>
<p>The immunogenicity of GARDASIL was assessed in 23,951 9- through 45-year-old girls and women (GARDASIL N = 12,634; AAHS control or saline placebo N = 11,317) and 5417 9- through 26-year-old boys and men (GARDASIL N = 3109; AAHS control or saline placebo N = 2308).</p>
<p>Type-specific immunoassays with type-specific standards were used to assess immunogenicity to each vaccine HPV type. These assays measured antibodies against neutralizing epitopes for each HPV type. The scales for these assays are unique to each HPV type; thus, comparisons across types and to other assays are not appropriate.</p>
<p><span class="Italics">Immune Response to GARDASIL</span></p>
<p>The primary immunogenicity analyses were conducted in a per-protocol immunogenicity (PPI) population. This population consisted of individuals who were seronegative and PCR negative to the relevant HPV type(s) at enrollment, remained HPV PCR negative to the relevant HPV type(s) through 1 month postdose 3 (Month 7), received all 3 vaccinations, and did not deviate from the study protocol in ways that could interfere with the effects of the vaccine.</p>
<p>Immunogenicity was measured by (1) the percentage of individuals who were seropositive for antibodies against the relevant vaccine HPV type, and (2) the Geometric Mean Titer (GMT).</p>
<p>In clinical studies in 16- through 26-year-old girls and women, 99.8%, 99.8%, 99.8%, and 99.4% who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month postdose 3 across all age groups tested.</p>
<p>In clinical studies in 27- through 45-year-old women, 98.2%, 97.9%, 98.6%, and 97.1% who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month postdose 3 across all age groups tested.</p>
<p>In clinical studies in 16- through 26-year-old boys and men, 98.9%, 99.2%, 98.8%, and 97.4% who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month postdose 3 across all age groups tested.</p>
<p>Across all populations, anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs peaked at Month 7 (Table 18 and Table 19). GMTs declined through Month 24 and then stabilized through Month 36 at levels above baseline. Tables 20 and 21 display the persistence of anti-HPV cLIA geometric mean titers by gender and age group. The duration of immunity following a complete schedule of immunization with GARDASIL has not been established.</p>
<a name="id_50f0622a-c431-4e92-bf89-702ca83915b6"></a><table width="730.000">
<caption><span>Table 18: Summary of Month 7 Anti-HPV cLIA Geometric Mean Titers in the PPI<a href="#footnote-1">*</a> Population of Girls and Women</span></caption>
<col span="1" width="36.2%">
<col span="1" width="8.2%">
<col span="1" width="8.2%">
<col span="1" width="21.1%">
<col span="1" width="26.3%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Population</span></td>
<td>
<span class="Bold">N</span><a href="#footnote-2">†</a>
</td>
<td>
<span class="Bold">n</span><a href="#footnote-3">‡</a>
</td>
<td><span class="Bold">% Seropositive<br>(95% CI)</span></td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-4">§</a>/mL</span></td>
</tr>
<tr><td><span class="Bold">Anti-HPV 6</span></td></tr>
<tr>
<td>9- through 15-year-old girls </td>
<td>1122</td>
<td>917</td>
<td>99.9 (99.4, 100.0)</td>
<td>929.2 (874.6, 987.3)</td>
</tr>
<tr>
<td>16- through 26-year-old girls and women</td>
<td>9859</td>
<td>3329</td>
<td>99.8 (99.6, 99.9)</td>
<td>545.0 (530.1, 560.4)</td>
</tr>
<tr>
<td>27- through 34-year-old women</td>
<td>667</td>
<td>439</td>
<td>98.4 (96.7, 99.4)</td>
<td>435.6 (393.4, 482.4)</td>
</tr>
<tr>
<td>35- through 45-year-old women</td>
<td>957</td>
<td>644</td>
<td>98.1 (96.8, 99.0)</td>
<td>397.3 (365.2, 432.2)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 11</span></td></tr>
<tr>
<td>9- through 15-year-old girls</td>
<td>1122</td>
<td>917</td>
<td>99.9 (99.4, 100.0)</td>
<td>1304.6 (1224.7, 1389.7)</td>
</tr>
<tr>
<td>16- through 26-year-old girls and women</td>
<td>9859</td>
<td>3353</td>
<td>99.8 (99.5, 99.9)</td>
<td>748.9 (726.0, 772.6)</td>
</tr>
<tr>
<td>27- through 34-year-old women</td>
<td>667</td>
<td>439</td>
<td>98.2 (96.4, 99.2)</td>
<td>577.9 (523.8, 637.5)</td>
</tr>
<tr>
<td>35- through 45-year-old women</td>
<td>957</td>
<td>644</td>
<td>97.7 (96.2, 98.7)</td>
<td>512.8 (472.9, 556.1)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 16</span></td></tr>
<tr>
<td>9- through 15-year-old girls</td>
<td>1122</td>
<td>915</td>
<td>99.9 (99.4, 100.0)</td>
<td>4918.5 (4556.6, 5309.1)</td>
</tr>
<tr>
<td>16- through 26-year-old girls and women</td>
<td>9859</td>
<td>3249</td>
<td>99.8 (99.6, 100.0)</td>
<td>2409.2 (2309.0, 2513.8)</td>
</tr>
<tr>
<td>27- through 34-year-old women</td>
<td>667</td>
<td>435</td>
<td>99.3 (98.0, 99.9)</td>
<td>2342.5 (2119.1, 2589.6)</td>
</tr>
<tr>
<td>35- through 45-year-old women</td>
<td>957</td>
<td>657</td>
<td>98.2 (96.8, 99.1)</td>
<td>2129.5 (1962.7, 2310.5)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 18</span></td></tr>
<tr>
<td>9- through 15-year-old girls</td>
<td>1122</td>
<td>922</td>
<td>99.8 (99.2, 100.0)</td>
<td>1042.6 (967.6, 1123.3)</td>
</tr>
<tr>
<td>16- through 26-year-old girls and women</td>
<td>9859</td>
<td>3566</td>
<td>99.4 (99.1, 99.7)</td>
<td>475.2 (458.8, 492.1)</td>
</tr>
<tr>
<td>27- through 34-year-old women</td>
<td>667</td>
<td>501</td>
<td>98.0 (96.4, 99.0)</td>
<td>385.8 (347.6, 428.1)</td>
</tr>
<tr class="Last">
<td>35- through 45-year-old women</td>
<td>957</td>
<td>722</td>
<td>96.4 (94.8, 97.6)</td>
<td>324.6 (297.6, 354.0)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-54" href="#footnote-54" class="Sup">54</a></p>
<p><a name="footnote-reference-55" href="#footnote-55" class="Sup">55</a></p>
<p><a name="footnote-reference-56" href="#footnote-56" class="Sup">56</a></p>
<p><a name="footnote-reference-57" href="#footnote-57" class="Sup">57</a></p>
<a name="id_1ca144f0-854b-432a-a207-34ffc686d887"></a><table width="730.000">
<caption><span>Table 19: Summary of Month 7 Anti-HPV cLIA Geometric Mean Titers in the PPI<a href="#footnote-5">*</a> Population of Boys and Men</span></caption>
<col span="1" width="36.2%">
<col span="1" width="8.2%">
<col span="1" width="8.2%">
<col span="1" width="21.1%">
<col span="1" width="26.3%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Population</span></td>
<td>
<span class="Bold">N</span><a href="#footnote-6">†</a>
</td>
<td>
<span class="Bold">n</span><a href="#footnote-7">‡</a>
</td>
<td><span class="Bold">% Seropositive<br>(95% CI)</span></td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-8">§</a>/mL</span></td>
</tr>
<tr><td><span class="Bold">Anti-HPV 6</span></td></tr>
<tr>
<td>9- through 15-year-old boys </td>
<td>1072</td>
<td>884</td>
<td>99.9 (99.4, 100.0)</td>
<td>1037.5 (963.5, 1117.3)</td>
</tr>
<tr>
<td>16- through 26-year-old boys and men</td>
<td>2026</td>
<td>1093</td>
<td>98.9 (98.1, 99.4)</td>
<td>447.8 (418.9, 478.6)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 11</span></td></tr>
<tr>
<td>9- through 15-year-old boys </td>
<td>1072</td>
<td>885</td>
<td>99.9 (99.4, 100.0)</td>
<td>1386.8 (1298.5, 1481.0)</td>
</tr>
<tr>
<td>16- through 26-year-old boys and men</td>
<td>2026</td>
<td>1093</td>
<td>99.2 (98.4, 99.6)</td>
<td>624.3 (588.4, 662.3)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 16</span></td></tr>
<tr>
<td>9- through 15-year-old boys </td>
<td>1072</td>
<td>882</td>
<td>99.8 (99.2, 100.0)</td>
<td>6056.5 (5601.3, 6548.7)</td>
</tr>
<tr>
<td>16- through 26-year-old boys and men</td>
<td>2026</td>
<td>1136</td>
<td>98.8 (97.9, 99.3)</td>
<td>2403.3 (2243.4, 2574.6)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 18</span></td></tr>
<tr>
<td>9- through 15-year-old boys </td>
<td>1072</td>
<td>887</td>
<td>99.8 (99.2, 100)</td>
<td>1357.4 (1249.4, 1474.7)</td>
</tr>
<tr class="Last">
<td>16- through 26-year-old boys and men</td>
<td>2026</td>
<td>1175</td>
<td>97.4 (96.3, 98.2)</td>
<td>402.6 (374.6, 432.7)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-58" href="#footnote-58" class="Sup">58</a></p>
<p><a name="footnote-reference-59" href="#footnote-59" class="Sup">59</a></p>
<p><a name="footnote-reference-60" href="#footnote-60" class="Sup">60</a></p>
<p><a name="footnote-reference-61" href="#footnote-61" class="Sup">61</a></p>
<a name="id_ef939801-3073-4313-acf3-af230b869116"></a><table width="741">
<caption><span>Table 20: Persistence of Anti-HPV cLIA Geometric Mean Titers in 9- Through 45-Year-Old Girls and Women</span></caption>
<col span="1" width="15.5%">
<col span="1" width="5.9%">
<col span="1" width="15.5%">
<col span="1" width="5.9%">
<col span="1" width="14.8%">
<col span="1" width="5.9%">
<col span="1" width="15.5%">
<col span="1" width="5.9%">
<col span="1" width="14.8%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Assay (cLIA)/ Time Point</span></td>
<td>
<p class="First"><span class="Bold">9- to 15-Year-Old Girls</span></p>
<span class="Bold">(N<a href="#footnote-9">*</a> = 1122)</span>
</td>
<td>
<p class="First"><span class="Bold">16- to 26-Year-Old Girls and Women</span></p>
<span class="Bold">(N <a href="#footnote-62" class="Sup">62</a> = 9859)</span>
</td>
<td>
<p class="First"><span class="Bold">27- to 34-Year-Old Women</span></p>
<span class="Bold">(N<span class="Bold"><a href="#footnote-62" class="Sup">62</a></span> = 667)</span>
</td>
<td>
<p class="First"><span class="Bold">35- to 45-Year-Old Women</span></p>
<span class="Bold">(N<span class="Bold"><a href="#footnote-62" class="Sup">62</a></span> = 957)</span>
</td>
</tr>
<tr>
<td>
<span class="Bold">n</span><a href="#footnote-10">†</a>
</td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-11">‡</a>/mL</span></td>
<td>
<span class="Bold">n</span><a href="#footnote-63" class="Sup">63</a>
</td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-64" class="Sup">64</a>/mL</span></td>
<td>
<span class="Bold">n</span><a href="#footnote-63" class="Sup">63</a>
</td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-64" class="Sup">64</a>/mL</span></td>
<td>
<span class="Bold">n</span><a href="#footnote-63" class="Sup">63</a>
</td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-64" class="Sup">64</a>/mL</span></td>
</tr>
<tr><td><span class="Bold">Anti-HPV 6</span></td></tr>
<tr>
<td>Month 07</td>
<td>917</td>
<td>
<p class="First">929.2 </p>(874.6, 987.3)</td>
<td>3329</td>
<td>
<p class="First">545.0</p>(530.1, 560.4)</td>
<td>439</td>
<td>
<p class="First">435.6 </p>(393.4, 482.4)</td>
<td>644</td>
<td>
<p class="First">397.3</p>(365.2, 432.2)</td>
</tr>
<tr>
<td>Month 24</td>
<td>214</td>
<td>
<p class="First">156.1 </p>(135.6, 179.6)</td>
<td>2788</td>
<td>
<p class="First">109.1 </p>(105.2, 113.1)</td>
<td>421</td>
<td>
<p class="First">70.7 </p>(63.8, 78.5)</td>
<td>628</td>
<td>
<p class="First">69.3</p>(63.7, 75.4)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-12">§</a>
</td>
<td>356</td>
<td>
<p class="First">129.4 </p>(115.6, 144.8)</td>
<td>-</td>
<td>-</td>
<td>399</td>
<td>
<p class="First">79.5 </p>(72.0, 87.7)</td>
<td>618</td>
<td>
<p class="First">81.1 </p>(75.0, 87.8)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-13">¶</a>
</td>
<td>-</td>
<td>-</td>
<td>2514</td>
<td>73.8 (70.9, 76.8)</td>
<td>391</td>
<td>
<p class="First">58.8 </p>(52.9, 65.3)</td>
<td>616</td>
<td>
<p class="First">62.0</p>(57.0, 67.5)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 11</span></td></tr>
<tr>
<td>Month 07</td>
<td>917</td>
<td>
<p class="First">1304.6</p>(1224.7, 1389.7)</td>
<td>3353</td>
<td>
<p class="First">748.9 </p>(726.0, 772.6)</td>
<td>439</td>
<td>
<p class="First">577.9</p>(523.8, 637.5)</td>
<td>644</td>
<td>
<p class="First">512.8</p>(472.9, 556.1)</td>
</tr>
<tr>
<td>Month 24</td>
<td>214</td>
<td>
<p class="First">218.0 </p>(188.3, 252.4)</td>
<td>2817</td>
<td>
<p class="First">137.1 </p>(132.1, 142.3)</td>
<td>421</td>
<td>
<p class="First">79.3 </p>(71.5, 87.8)</td>
<td>628</td>
<td>
<p class="First">73.4 </p>(67.4, 79.8)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-65" class="Sup">65</a>
</td>
<td>356</td>
<td>
<p class="First">148.0 </p>(131.1, 167.1)</td>
<td>-</td>
<td>-</td>
<td>399</td>
<td>
<p class="First">81.8 </p>(74.3, 90.1)</td>
<td>618</td>
<td>
<p class="First">77.4 </p>(71.6, 83.6)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-66" class="Sup">66</a>
</td>
<td>-</td>
<td>-</td>
<td>2538</td>
<td>
<p class="First">89.4</p>(85.9, 93.1)</td>
<td>391</td>
<td>
<p class="First">67.4 </p>(60.9, 74.7)</td>
<td>616</td>
<td>
<p class="First">62.7</p>(57.8, 68.0)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 16</span></td></tr>
<tr>
<td>Month 07</td>
<td>915</td>
<td>
<p class="First">4918.5 </p>(4556.6, 5309.1)</td>
<td>3249</td>
<td>
<p class="First">2409.2 </p>(2309.0, 2513.8)</td>
<td>435</td>
<td>
<p class="First">2342.5</p>(2119.1, 2589.6)</td>
<td>657</td>
<td>
<p class="First">2129.5 </p>(1962.7, 2310.5)</td>
</tr>
<tr>
<td>Month 24</td>
<td>211</td>
<td>
<p class="First">944.2 </p>(804.4, 1108.3)</td>
<td>2721</td>
<td>
<p class="First">442.6 </p>(425.0, 460.9)</td>
<td>416</td>
<td>
<p class="First">285.9 </p>(254.4, 321.2)</td>
<td>642</td>
<td>
<p class="First">271.4 </p>(247.1, 298.1)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-65" class="Sup">65</a>
</td>
<td>353</td>
<td>
<p class="First">642.2 </p>(562.8, 732.8)</td>
<td>-</td>
<td>-</td>
<td>399</td>
<td>
<p class="First">291.5 </p>(262.5, 323.8)</td>
<td>631</td>
<td>
<p class="First">276.7 </p>(254.5, 300.8)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-66" class="Sup">66</a>
</td>
<td>-</td>
<td>-</td>
<td>2474</td>
<td>
<p class="First">326.2 </p>(311.8, 341.3)</td>
<td>394</td>
<td>
<p class="First">211.8 </p>(189.5, 236.8)</td>
<td>628</td>
<td>
<p class="First">192.8 </p>(176.5, 210.6)</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 18</span></td></tr>
<tr>
<td>Month 07</td>
<td>922</td>
<td>
<p class="First">1042.6 </p>(967.6, 1123.3)</td>
<td>3566</td>
<td>
<p class="First">475.2</p>(458.8, 492.1)</td>
<td>501</td>
<td>
<p class="First">385.8 </p>(347.6, 428.1)</td>
<td>722</td>
<td>
<p class="First">324.6 </p>(297.6, 354.0)</td>
</tr>
<tr>
<td>Month 24</td>
<td>214</td>
<td>
<p class="First">137.7 </p>(114.8, 165.1)</td>
<td>3002</td>
<td>
<p class="First">50.8 </p>(48.2, 53.5)</td>
<td>478</td>
<td>
<p class="First">31.8 </p>(28.1, 36.0)</td>
<td>705</td>
<td>
<p class="First">26.0 </p>(23.5, 28.8)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-65" class="Sup">65</a>
</td>
<td>357</td>
<td>
<p class="First">87.0 </p>(74.8, 101.2)</td>
<td>-</td>
<td>-</td>
<td>453</td>
<td>
<p class="First">32.1 </p>(28.5, 36.3)</td>
<td>689</td>
<td>
<p class="First">27.0 </p>(24.5, 29.8)</td>
</tr>
<tr class="Last">
<td>Month 48<a href="#footnote-66" class="Sup">66</a>
</td>
<td>-</td>
<td>-</td>
<td>2710</td>
<td>
<p class="First">33.2 </p>(31.5, 35.0)</td>
<td>444</td>
<td>
<p class="First">25.2 </p>(22.3, 28.5)</td>
<td>688</td>
<td>
<p class="First">21.2 </p>(19.2, 23.4)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-62" href="#footnote-62" class="Sup">62</a></p>
<p><a name="footnote-reference-63" href="#footnote-63" class="Sup">63</a></p>
<p><a name="footnote-reference-64" href="#footnote-64" class="Sup">64</a></p>
<p><a name="footnote-reference-65" href="#footnote-65" class="Sup">65</a></p>
<p><a name="footnote-reference-66" href="#footnote-66" class="Sup">66</a></p>
<a name="id_3dbcf973-c0c2-43ea-9108-20a92d9d5c56"></a><table width="543">
<caption><span>Table 21: Persistence of Anti-HPV cLIA Geometric Mean Titers in 9- Through 26-Year-Old Boys and Men</span></caption>
<col span="1" width="23.4%">
<col span="1" width="15.1%">
<col span="1" width="24.3%">
<col span="1" width="15.1%">
<col span="1" width="24.3%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Assay (cLIA)/ Time Point</span></td>
<td>
<p class="First"><span class="Bold">9- to 15-Year-Old Boys</span></p>
<span class="Bold">(N<a href="#footnote-14">*</a> = 1072)</span>
</td>
<td>
<p class="First"><span class="Bold">16- to 26-Year-Old Boys and Men</span></p>
<span class="Bold">(N<a href="#footnote-67" class="Sup">67</a> = 2026)</span>
</td>
</tr>
<tr>
<td><span class="Bold">n<a href="#footnote-15">†</a></span></td>
<td><span class="Bold">GMT <br>(95% CI) mMU<span class="Bold"><a href="#footnote-16">‡</a></span>/mL</span></td>
<td><span class="Bold">n<span class="Bold"><a href="#footnote-68" class="Sup">68</a></span></span></td>
<td><span class="Bold">GMT <br>(95% CI) mMU<a href="#footnote-69" class="Sup">69</a>/mL</span></td>
</tr>
<tr><td><span class="Bold">Anti-HPV 6</span></td></tr>
<tr>
<td>Month 07</td>
<td>884</td>
<td>
<p class="First">1037.5 </p>(963.5, 1117.3)</td>
<td>1094</td>
<td>
<p class="First">447.2 </p>(418.4, 477.9)</td>
</tr>
<tr>
<td>Month 24</td>
<td>323</td>
<td>
<p class="First">134.1 </p>(119.5, 150.5)</td>
<td>907</td>
<td>
<p class="First">80.3 </p>(74.9, 86.0)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-17">§</a>
</td>
<td>342</td>
<td>
<p class="First">126.6 </p>(111.9, 143.2)</td>
<td>654</td>
<td>
<p class="First">72.4 </p>(68.0, 77.2)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-18">¶</a>
</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 11</span></td></tr>
<tr>
<td>Month 07</td>
<td>885</td>
<td>
<p class="First">1386.8 </p>(1298.5, 1481.0)</td>
<td>1094</td>
<td>
<p class="First">624.5 </p>(588.6, 662.5)</td>
</tr>
<tr>
<td>Month 24</td>
<td>324</td>
<td>
<p class="First">188.5 </p>(168.4, 211.1)</td>
<td>907</td>
<td>
<p class="First">94.6 </p>(88.4, 101.2)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-70" class="Sup">70</a>
</td>
<td>342</td>
<td>
<p class="First">148.8 </p>(131.1, 169.0)</td>
<td>654</td>
<td>
<p class="First">80.3 </p>(75.7, 85.2)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-71" class="Sup">71</a>
</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 16</span></td></tr>
<tr>
<td>Month 07</td>
<td>882</td>
<td>
<p class="First">6056.5 </p>(5601.4, 6548.6)</td>
<td>1137</td>
<td>
<p class="First">2401.5 </p>(2241.8, 2572.6)</td>
</tr>
<tr>
<td>Month 24</td>
<td>322</td>
<td>
<p class="First">938.2 </p>(825.0, 1067.0)</td>
<td>938</td>
<td>
<p class="First">347.7 </p>(322.5, 374.9)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-70" class="Sup">70</a>
</td>
<td>341</td>
<td>
<p class="First">708.8 </p>(613.9, 818.3)</td>
<td>672</td>
<td>
<p class="First">306.7 </p>(287.5, 327.1)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-71" class="Sup">71</a>
</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr><td><span class="Bold">Anti-HPV 18</span></td></tr>
<tr>
<td>Month 07</td>
<td>887</td>
<td>
<p class="First">1357.4 </p>(1249.4, 1474.7)</td>
<td>1176</td>
<td>
<p class="First">402.6 </p>(374.6, 432.6)</td>
</tr>
<tr>
<td>Month 24</td>
<td>324</td>
<td>
<p class="First">131.9 </p>(112.1, 155.3)</td>
<td>967</td>
<td>
<p class="First">38.7 </p>(35.2, 42.5)</td>
</tr>
<tr>
<td>Month 36<a href="#footnote-70" class="Sup">70</a>
</td>
<td>343</td>
<td>
<p class="First">113.0 </p>(94.7, 135.0)</td>
<td>690</td>
<td>
<p class="First">33.4 </p>(30.9, 36.1)</td>
</tr>
<tr>
<td>Month 48<a href="#footnote-71" class="Sup">71</a>
</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr><td>cLIA = Competitive Luminex Immunoassay<br>CI = Confidence Interval<br>GMT = Geometric Mean Titers</td></tr>
<tr class="Last"><td><br></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-67" href="#footnote-67" class="Sup">67</a></p>
<p><a name="footnote-reference-68" href="#footnote-68" class="Sup">68</a></p>
<p><a name="footnote-reference-69" href="#footnote-69" class="Sup">69</a></p>
<p><a name="footnote-reference-70" href="#footnote-70" class="Sup">70</a></p>
<p><a name="footnote-reference-71" href="#footnote-71" class="Sup">71</a></p>
<p>Tables 18 and 19 display the Month 7 immunogenicity data for girls and women and boys and men. Anti-HPV responses 1 month postdose 3 among 9- through 15-year-old adolescent girls were non-inferior to anti-HPV responses in 16- through 26-year-old girls and women in the combined database of immunogenicity studies for GARDASIL. Anti-HPV responses 1 month postdose 3 among 9- through 15-year-old adolescent boys were non-inferior to anti-HPV responses in 16- through 26-year-old boys and men in Study 5.</p>
<p>On the basis of this immunogenicity bridging, the efficacy of GARDASIL in 9- through 15-year-old adolescent girls and boys is inferred. </p>
<p><span class="Italics">GMT Response to Variation in Dosing Regimen in 18- Through 26-Year-Old Women </span></p>
<p>Girls and women evaluated in the PPE population of clinical studies received all 3 vaccinations within 1 year of enrollment. An analysis of immune response data suggests that flexibility of ±1 month for Dose 2 (i.e., Month 1 to Month 3 in the vaccination regimen) and flexibility of ±2 months for Dose 3 (i.e., Month 4 to Month 8 in the vaccination regimen) do not impact the immune responses to GARDASIL.</p>
<p><span class="Italics">Duration of the Immune Response to GARDASIL</span></p>
<p>The duration of immunity following a complete schedule of immunization with GARDASIL has not been established. The peak anti-HPV GMTs for HPV types 6, 11, 16, and 18 occurred at Month 7. Anti-HPV GMTs for HPV types 6, 11, 16, and 18 were similar between measurements at Month 24 and Month 60 in Study 2.</p>
<p>
 
</p>
<p></p>
<p>The safety and immunogenicity of co-administration of GARDASIL with RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] (same visit, injections at separate sites) were evaluated in a randomized, double-blind, study of 1871 women aged 16 through 24 years at enrollment. The race distribution of the girls and women in the clinical trial was as follows: 61.6% White; 1.6% Hispanic (Black and White); 23.8% Other; 11.9% Black; 0.8% Asian; and 0.3% American Indian.</p>
<p>Subjects either received GARDASIL and RECOMBIVAX HB (n = 466), GARDASIL and RECOMBIVAX HB-matched placebo (n = 468), RECOMBIVAX HB and GARDASIL-matched placebo (n = 467) or RECOMBIVAX-matched placebo and GARDASIL-matched placebo (n = 470) at Day 1, Month 2 and Month 6. Immunogenicity was assessed for all vaccines 1 month post completion of the vaccination series. </p>
<p>Concomitant administration of GARDASIL with RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] did not interfere with the antibody response to any of the vaccine antigens when GARDASIL was given concomitantly with RECOMBIVAX HB or separately.</p>
<p>
 
</p>
<p></p>
<p>The safety and immunogenicity of co-administration of GARDASIL with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)] (same visit, injections at separate sites) were evaluated in an open-labeled, randomized, controlled study of 1040 boys and girls 11 through 17 years of age at enrollment. The race distribution of the subjects in the clinical trial was as follows: 77.7% White; 6.8% Hispanic (Black and White); 1.4% Multi-racial; 12.3% Black; 1.2% Asian; 0.2% Indian; and 0.4% American Indian.</p>
<p>One group received GARDASIL in one limb and both Menactra and Adacel, as separate injections, in the opposite limb concomitantly on Day 1 (n = 517). The second group received the first dose of GARDASIL on Day 1 in one limb then Menactra and Adacel, as separate injections, at Month 1 in the opposite limb (n = 523). Subjects in both vaccination groups received the second dose of GARDASIL at Month 2 and the third dose at Month 6. Immunogenicity was assessed for all vaccines 1 month post completion of the vaccination series (1 dose for Menactra and Adacel and 3 doses for GARDASIL). </p>
<p>Concomitant administration of GARDASIL with Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)] did not interfere with the antibody response to any of the vaccine antigens when GARDASIL was given concomitantly with Menactra and Adacel or separately.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">31</a></dt>
<dd>The PPE population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (Month 7).</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">32</a></dt>
<dd>See </dd>
<dt><a name="footnote-33" href="#footnote-reference-33">33</a></dt>
<dd>Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL</dd>
<dt><a name="footnote-34" href="#footnote-reference-34">34</a></dt>
<dd>Analyses of the combined trials were prospectively planned and included the use of similar study entry criteria.</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">35</a></dt>
<dd>The PPE population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (Month 7).</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">36</a></dt>
<dd>N = Number of individuals with at least 1 follow-up visit after Month 7</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">37</a></dt>
<dd>The PPE population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (month 7).</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">38</a></dt>
<dd>N = Number of individuals with at least 1 follow-up visit after Month 7</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">39</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who were HPV-naïve (i.e., seronegative and PCR negative) at Day 1 to the vaccine HPV type being analyzed. Case counting started at 1 month postdose 1.</dd>
<dt><a name="footnote-40" href="#footnote-reference-40">40</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who were HPV positive or had unknown HPV status at Day 1, to at least one vaccine HPV type. Case counting started at Day 1.</dd>
<dt><a name="footnote-41" href="#footnote-reference-41">41</a></dt>
<dd>Out of the 148 AAHS control cases of 16/18 CIN 2/3, 2 women were missing serology or PCR results for Day 1.</dd>
<dt><a name="footnote-42" href="#footnote-reference-42">42</a></dt>
<dd>There is no expected efficacy since GARDASIL has not been demonstrated to provide protection against disease from vaccine HPV types to which a person has previously been exposed through sexual activity.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">43</a></dt>
<dd>Includes all individuals who received at least 1 vaccination (regardless of baseline HPV status at Day 1). Case counting started at 1 month postdose 1.</dd>
<dt><a name="footnote-44" href="#footnote-reference-44">44</a></dt>
<dd>Includes 2 AAHS control women with missing serology/PCR data at Day 1.</dd>
<dt><a name="footnote-45" href="#footnote-reference-45">45</a></dt>
<dd>Includes 1 woman with missing serology/PCR data at Day 1.</dd>
<dt><a name="footnote-46" href="#footnote-reference-46">46</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who had a Pap test that was negative for SIL [Squamous Intraepithelial Lesion] at Day 1 and were naïve to 14 common HPV types at Day 1. Case counting started at 1 month postdose 1.</dd>
<dt><a name="footnote-47" href="#footnote-reference-47">47</a></dt>
<dd>Includes all individuals who received at least 1 vaccination (regardless of baseline HPV status or Pap test result at Day 1). Case counting started at 1 month postdose 1.</dd>
<dt><a name="footnote-48" href="#footnote-reference-48">48</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who were HPV-naïve (i.e., seronegative and PCR negative) at Day 1 to the vaccine HPV type being analyzed. Case counting started at Day 1.</dd>
<dt><a name="footnote-49" href="#footnote-reference-49">49</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who were HPV positive or had unknown HPV status at Day 1, to at least one vaccine HPV type. Case counting started at Day 1.</dd>
<dt><a name="footnote-50" href="#footnote-reference-50">50</a></dt>
<dd>There is no expected efficacy since GARDASIL has not been demonstrated to provide protection against disease from vaccine HPV types to which a person has previously been exposed through sexual activity.</dd>
<dt><a name="footnote-51" href="#footnote-reference-51">51</a></dt>
<dd>Includes all individuals who received at least 1 vaccination. Case counting started at Day 1.</dd>
<dt><a name="footnote-52" href="#footnote-reference-52">52</a></dt>
<dd>Includes all individuals who received at least 1 vaccination and who were seronegative and PCR negative at enrollment to HPV 6, 11, 16 and 18, and PCR negative at enrollment to HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. Case counting started at Day 1.</dd>
<dt><a name="footnote-53" href="#footnote-reference-53">53</a></dt>
<dd>Includes all individuals who received at least 1 vaccination. Case counting started at Day 1.</dd>
<dt><a name="footnote-54" href="#footnote-reference-54">54</a></dt>
<dd>The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).</dd>
<dt><a name="footnote-55" href="#footnote-reference-55">55</a></dt>
<dd>Number of individuals randomized to the respective vaccination group who received at least 1 injection.</dd>
<dt><a name="footnote-56" href="#footnote-reference-56">56</a></dt>
<dd>Number of individuals contributing to the analysis.</dd>
<dt><a name="footnote-57" href="#footnote-reference-57">57</a></dt>
<dd>mMU = milli-Merck Units</dd>
<dt><a name="footnote-58" href="#footnote-reference-58">58</a></dt>
<dd>The PPI population consisted of individuals who received all 3 vaccinations within pre-defined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).</dd>
<dt><a name="footnote-59" href="#footnote-reference-59">59</a></dt>
<dd>Number of individuals randomized to the respective vaccination group who received at least 1 injection.</dd>
<dt><a name="footnote-60" href="#footnote-reference-60">60</a></dt>
<dd>Number of individuals contributing to the analysis.</dd>
<dt><a name="footnote-61" href="#footnote-reference-61">61</a></dt>
<dd>mMU = milli-Merck Units</dd>
<dt><a name="footnote-62" href="#footnote-reference-62">62</a></dt>
<dd>N = Number of individuals randomized in the respective group who received at least 1 injection.</dd>
<dt><a name="footnote-63" href="#footnote-reference-63">63</a></dt>
<dd>n = Number of individuals in the indicated immunogenicity population.</dd>
<dt><a name="footnote-64" href="#footnote-reference-64">64</a></dt>
<dd>mMU = milli-Merck Units</dd>
<dt><a name="footnote-65" href="#footnote-reference-65">65</a></dt>
<dd>Month 37 for 9- to 15-year-old girls. No serology samples were collected at this time point for 16- to 26-year-old girls and women.</dd>
<dt><a name="footnote-66" href="#footnote-reference-66">66</a></dt>
<dd>Month 48/End-of-study visits for 16- to 26-year-old girls and women were generally scheduled earlier than Month 48. Mean visit timing was Month 44. The studies in 9- to 15-year-old girls were planned to end prior to 48 months and therefore no serology samples were collected.</dd>
<dt><a name="footnote-67" href="#footnote-reference-67">67</a></dt>
<dd>N = Number of individuals randomized in the respective group who received at least 1 injection.</dd>
<dt><a name="footnote-68" href="#footnote-reference-68">68</a></dt>
<dd>n = Number of individuals in the indicated immunogenicity population.</dd>
<dt><a name="footnote-69" href="#footnote-reference-69">69</a></dt>
<dd>mMU = milli-Merck Units</dd>
<dt><a name="footnote-70" href="#footnote-reference-70">70</a></dt>
<dd>Month 36 time point for 16- to 26-year-old boys and men; Month 37 for 9- to 15-year-old boys.</dd>
<dt><a name="footnote-71" href="#footnote-reference-71">71</a></dt>
<dd>The studies in 9- to 15-year-old boys and girls and 16- to 26-year-old boys and men were planned to end prior to 48 months and therefore no serology samples were collected.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>All presentations for GARDASIL contain a suspension of 120 mcg L1 protein from HPV types 6, 11, 16, and 18 in a 0.5-mL dose. GARDASIL is supplied in vials and syringes. </p>
<p>Carton of one 0.5-mL single-dose vial. <span class="Bold">NDC</span> 0006-4045-00.</p>
<p>Carton of ten 0.5-mL single-dose vials. <span class="Bold">NDC</span> 0006-4045-41.</p>
<p>Carton of six 0.5-mL single-dose prefilled Luer Lock syringes with tip caps. <span class="Bold">NDC</span> 0006-4109-09.</p>
<p>Store refrigerated at 2 to 8°C (36 to 46°F). Do not freeze. Protect from light.</p>
<p>GARDASIL should be administered as soon as possible after being removed from refrigeration.</p>
<p>GARDASIL can be out of refrigeration (at temperatures at or below 25°C/77°F), for a total time of not more than 72 hours. </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>See <a href="#i4i_patient_package_insert_id_f6daa288-d827-4cd1-b64f-36e79039937c">FDA-Approved Patient Labeling (Patient Information)</a>.</p>
<p>Inform the patient, parent, or guardian:</p>
<ul>
<li>Vaccination does not eliminate the necessity for women to continue to undergo recommended cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care.</li>
<li>Recipients of GARDASIL should not discontinue anal cancer screening if it has been recommended by a health care provider.</li>
<li>GARDASIL has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a person has previously been exposed through sexual activity. </li>
<li>Since <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> has been reported following vaccination sometimes resulting in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> with injury, observation for 15 minutes after administration is recommended. </li>
<li>Vaccine information is required to be given with each vaccination to the patient, parent, or guardian.</li>
<li>Information regarding benefits and risks associated with vaccination. </li>
<li>GARDASIL is not recommended for use in pregnant women.</li>
<li>Importance of completing the immunization series unless contraindicated.</li>
<li>Report any adverse reactions to their health care provider.</li>
</ul>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Manuf. and Dist. by: Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>The trademarks depicted herein are owned by their respective companies.</p>
<p>Copyright © 2006, 2009, 2010, 2011 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>uspi-v501-i-1309r018</p>
<p>Printed in USA</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1>SPL PATIENT PACKAGE INSERT</h1>
<p class="First"></p>
<p><span class="Bold">USPPI<br>Patient Information about<br>GARDASIL<span class="Sup">®</span> (pronounced "gard-Ah-sill")<br>Generic name: [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]</span></p>
<p>Read this information with care before getting GARDASIL<span class="Sup">2</span>. You (the person getting GARDASIL) will need 3 doses of the vaccine. It is important to read this leaflet when you get each dose. This leaflet does not take the place of talking with your health care provider about GARDASIL.</p>
<p><span class="Bold">What is GARDASIL?</span></p>
<p>GARDASIL is a vaccine (injection/shot) that is used for girls and women 9 through 26 years of age to help protect against the following diseases caused by Human Papillomavirus (HPV): </p>
<ul>
<li>Cervical cancer </li>
<li>Vulvar and vaginal cancers </li>
<li>Anal cancer</li>
<li><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span> </li>
<li>Precancerous cervical, vaginal, vulvar, and anal lesions </li>
</ul>
<p>GARDASIL is used for boys and men 9 through 26 years of age to help protect against the following diseases caused by HPV:</p>
<ul>
<li>Anal cancer </li>
<li><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Genital warts</span></li>
<li>Precancerous anal lesions <ul>
<li>The diseases listed above have many causes, and GARDASIL only protects against diseases caused by certain kinds of HPV (called Type 6, Type 11, Type 16, and Type 18). Most of the time, these 4 types of HPV are responsible for the diseases listed above. </li>
<li>GARDASIL cannot protect you from a disease that is caused by other types of HPV, other viruses, or bacteria.</li>
<li>GARDASIL does not treat HPV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>You cannot get HPV or any of the above diseases from GARDASIL.</li>
</ul>
</li>
</ul>
<p><span class="Bold">What important information about GARDASIL should I know?</span></p>
<ul>
<li>You should continue to get routine cervical cancer screening.</li>
<li>GARDASIL may not fully protect everyone who gets the vaccine.</li>
<li>GARDASIL will not protect against HPV types that you already have.</li>
</ul>
<p><span class="Bold">Who should not get GARDASIL?</span></p>
<p>You should not get GARDASIL if you have, or have had:</p>
<ul>
<li>an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> after getting a dose of GARDASIL.</li>
<li>a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to yeast, amorphous aluminum hydroxyphosphate sulfate, polysorbate 80.</li>
</ul>
<p><span class="Bold">What should I tell my health care provider before getting GARDASIL?</span></p>
<p>Tell your health care provider if you: </p>
<ul>
<li>are pregnant or planning to get pregnant. GARDASIL is not recommended for use in pregnant women.</li>
<li>have immune problems, like <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, cancer, or you take medicines that affect your immune system.</li>
<li>have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> over 100°F (37.8°C). </li>
<li>had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to another dose of GARDASIL. </li>
<li>take any medicines, even those you can buy over the counter.</li>
</ul>
<p>Your health care provider will help decide if you should get the vaccine.</p>
<p><span class="Bold">How is GARDASIL given?</span></p>
<p>GARDASIL is a shot that is usually given in the arm muscle. You will need 3 shots given on the following schedule:</p>
<ul>
<li>Dose 1: at a date you and your health care provider choose.</li>
<li>Dose 2: 2 months after Dose 1.</li>
<li>Dose 3: 6 months after Dose 1.</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span> can happen after getting GARDASIL. Sometimes people who <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> can <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> and hurt themselves. For this reason, your health care provider may ask you to sit or lie down for 15 minutes after you get GARDASIL. Some people who <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> might shake or become stiff. This may require evaluation or treatment by your health care provider.</p>
<p>Make sure that you get all 3 doses on time so that you get the best protection. If you miss a dose, talk to your health care provider.</p>
<p><span class="Bold">Can other vaccines and medications be given at the same time as GARDASIL?</span></p>
<p>GARDASIL can be given at the same time as RECOMBIVAX HB<span class="Sup">®1</span> [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)] or Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)].</p>
<p><span class="Bold">What are the possible side effects of GARDASIL?</span></p>
<p>The most common side effects with GARDASIL are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> at the injection site</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
</ul>
<p>There was no increase in side effects when GARDASIL was given at the same time as RECOMBIVAX HB [<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B vaccine (recombinant)].</p>
<p>There was more injection-site <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> at the injection site for GARDASIL when GARDASIL was given at the same time as Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid Conjugate Vaccine] and Adacel [<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoid and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap)].</p>
<p>Tell your health care provider if you have any of the following problems because these may be signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></li>
<li><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul>
<p>Tell your health care provider if you have:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span> (neck, armpit, or groin)</li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li>generally <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">feeling unwell</span></li>
<li><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li>aching muscles</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></li>
<li>bad <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach ache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> more easily than normal</li>
<li><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span></li>
</ul>
<p>Contact your health care provider right away if you get any symptoms that concern you, even several months after getting the vaccine. </p>
<p>For a more complete list of side effects, ask your health care provider.</p>
<p><span class="Bold">What are the ingredients in GARDASIL?</span></p>
<p>The ingredients are proteins of HPV Types 6, 11, 16, and 18, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, polysorbate 80, sodium borate, and water for injection. </p>
<p>This leaflet is a summary of information about GARDASIL. If you would like more information, please talk to your health care provider or visit www.gardasil.com.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Manufactured and Distributed by: Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<br>Whitehouse Station, NJ 08889, USA</p>
<p>Issued April 2011</p>
<p>9883616</p>
<p><span class="Sup">2</span>Registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>  Copyright © 2006, 2009 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>  All rights reserved</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: GARDASIL </p>
<p><br></p>
<p>GENERIC: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant</p>
<p><br></p>
<p>DOSAGE: INJECTION, SUSPENSION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 52125-833-01</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul>
<li>HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN 40ug in 0.5mL</li>
<li>HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN 20ug in 0.5mL</li>
<li>HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN 40ug in 0.5mL</li>
<li>HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN 20ug in 0.5mL</li>
</ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>HISTIDINE</li>
<li>SODIUM CHLORIDE</li>
<li>SODIUM BORATE</li>
<li>POLYSORBATE 80</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>COLOR: white</p>
<p><br></p>
<p>PACKAGING: 0.5 mL in 1 VIAL, SINGLE-DOSE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=46a2bb5a-57f7-4747-a10f-488b2a60990d&amp;name=MM1.jpg"></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=46a2bb5a-57f7-4747-a10f-488b2a60990d&amp;name=MM2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GARDASIL 		
					</strong><br><span class="contentTableReg">human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-833(NDC:0006-4045)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN</strong> (HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN) </td>
<td class="formItem">HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN</td>
<td class="formItem">40 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN</strong> (HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN) </td>
<td class="formItem">HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN</td>
<td class="formItem">20 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN</strong> (HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN) </td>
<td class="formItem">HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN</td>
<td class="formItem">40 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN</strong> (HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN) </td>
<td class="formItem">HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN</td>
<td class="formItem">20 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BORATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-833-01</td>
<td class="formItem">0.5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125126</td>
<td class="formItem">02/13/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7df773ee-514e-4b02-a4a2-a97f649ee9e0</div>
<div>Set id: 46a2bb5a-57f7-4747-a10f-488b2a60990d</div>
<div>Version: 2</div>
<div>Effective Time: 20140213</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
